Epidermal growth factor stimulates intestinal epithelial cell migration through activation of the small GTPase Rac by Dise, Rebecca Susanne
EPIDERMAL GROWTH FACTOR STIMULATES INTESTINAL EPITHELIAL CELL 
MIGRATION THROUGH ACTIVATION OF THE SMALL GTPASE RAC 
 
By 
 
 
Rebecca Susanne Dise 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
 
 
DOCTOR OF PHILOSOPHY 
 
in 
 
Cell and Developmental Biology 
 
May, 2006 
 
Nashville, Tennessee 
 
Approved: 
D. Brent Polk 
Stephen R. Hann 
Raymond N. DuBois 
Ambra Pozzi 
Roy Zent 
 ii 
ACKNOWLEDGEMENTS 
 
 First and foremost I would like to thank my mentor, Dr. Brent Polk, for giving me 
the opportunity to work in his lab and pursue my love of cell signaling.  He has provided 
me with every opportunity and I am very grateful for that.  He has been an inspiring 
mentor and it has been a pleasure to work under his direction.  He has also managed to 
assemble an amazing team of scientists in his lab who have made the lab a fun and 
enjoyable place to work.  I would like to thank everyone in the lab for their friendship 
and support over the years, especially Dr. Mark Frey and Jeremy Goettel who have been 
a constant source of stimulating conversation for me, both scientifically and personally, 
for which I am very grateful.  I would also like to thank my committee members, Dr. 
Steve Hann, Dr. Raymond DuBois, Dr. Roy Zent, and Dr. Ambra Pozzi for all of their 
time and input into this project over the years, as well as their encouragement and 
support.  I would also like to thank Dr. Eduard Casillas and Dr. Valerie Kish at the 
University of Richmond who provided me with the first opportunities to do basic science.  
I am sure that I would not have come to graduate school without their encouragement and 
guidance during my undergraduate work.   
I would like to thank my family for all of their love and support, especially my 
parents who have graciously supported me intellectually, financially, and emotionally 
throughout my entire life making my dream of earning my Ph.D. attainable.  I would also 
like to thank all of my brothers and sisters who always put a smile on my face and who I 
know will always love me no matter what.  My family now includes Nelson and Cherie 
Wolfe, who have been so supportive of Ben and I both and have always encouraged us to 
pursue our dreams.  Finally, I would like to thank my newest family, my husband Ben 
 iii 
Wolfe and my precious kitty cat Nara.  Without Ben’s love and support through all of 
this, I would not be the person I am today.  I am so lucky to have him in my life and 
every day I love him even more. I would especially like to thank him for not only being 
my best friend, but for challenging me scientifically and encouraging me to set my 
standards high.     
 iv 
TABLE OF CONTENTS 
 
Page 
ACKNOWLEDGEMENTS............................................................................................ ii 
LIST OF FIGURES........................................................................................................vi 
LIST OF ABBREVIATIONS...................................................................................... viii 
Chapter 
I.   INTRODUCTION......................................................................................................1 
          Biology of the intestinal epithelium........................................................................1  
          Wound healing in the intestine ...............................................................................5 
          Cell migration and Rho GTPases ...........................................................................8 
          ErbB family of receptor tyrosine kinases..............................................................14 
          Signaling through epidermal growth factor receptor .............................................20 
                 Autophosphorylation sites .............................................................................21 
                 Activation of the mitogen activated protein kinase cascade............................21 
                 Activation of phosphoinositide 3-kinase........................................................24 
                 Activation of phospholipase Cγ .....................................................................26 
                 Receptor internalization and degradation.......................................................27 
                 Activation of Src family kinases....................................................................29 
          Summary .............................................................................................................32 
 
II.  MATERIALS AND METHODS..............................................................................34 
 
          Cell culture ..........................................................................................................34 
          Antibodies, growth factors, and pharmacological inhibitors .................................34 
          Transient transfections .........................................................................................36 
          Generation of stable cells .....................................................................................36 
          siRNA experiments..............................................................................................37 
          Cell lysis, SDS-PAGE, and Western blot analysis ................................................38 
          Rac activation assays ...........................................................................................39 
          Migration assays ..................................................................................................39 
          Immunofluorescence............................................................................................40 
          Immunoprecipitation............................................................................................41 
          Statistical analysis................................................................................................41 
 v 
III.  EPIDERMAL GROWTH FACTOR ACTIVATES THE SMALL GPTASE RAC1  
       TO STIMULATE INTESTINAL EPITHELIAL CELL MIGRATION 
 
          Introduction .........................................................................................................42 
          Results .................................................................................................................43 
                 Rac is required for EGF stimulated migration................................................43 
                 EGF rapidly activates Rac in YAMC cells.....................................................49 
                 EGFR kinase activity is required for EGF stimulated Rac activation .............54 
          Discussion ...........................................................................................................64 
 
IV.  RAC ACTIVATION REQUIRES PHOSPHOINOSITIDE 3-KINASE AND SRC    
       FAMILY KINASE ACTIVITY 
 
          Introduction .........................................................................................................70 
          Results .................................................................................................................71 
                PLC and PKCs are not required for Rac activation .........................................71 
                PI3K, but not Akt or MEK 1/2 activity, is required for Rac activation ............75 
                Src family kinases are required for Rac activation ..........................................78 
                Src and PI3K synergize to activate Rac ..........................................................82 
                Effect of tyrosine mutations on EGF stimulated signaling and migration........84 
          Discussion ...........................................................................................................88 
 
V. FUTURE DIRECTIONS AND CONCLUSIONS 
 
          Future directions ..................................................................................................96 
          Concluding remarks .............................................................................................98 
 
REFERENCES............................................................................................................100 
 
                 
 vi 
LIST OF FIGURES 
 
Figure Page 
1. Tissue anatomy of the small intestine........................................................................2 
2. Tissue anatomy of the colonic epithelium .................................................................4 
3. Restitution in the small intestine ...............................................................................6 
4. Cell migration.........................................................................................................10 
5. Regulation of Rho GTPases ....................................................................................12 
6. Structure of ErbB receptors and model of activation ...............................................16 
7. Structure of EGFR..................................................................................................22 
8. Wound closure assay ..............................................................................................44 
9. EGF stimulates lamellipodia formation at the wound margin ..................................46 
10. Rac is required for EGF stimulated migration .........................................................48 
11. EGF treatment of YAMC cells rapidly activates Rac ..............................................50 
12. Wounding activates Rac and sustains EGF stimulated Rac activation .....................53 
13. EGFR, but not ErbB2 is required for EGF stimulated Rac activation ......................55 
14. EGFR kinase activity is required for Rac activation ................................................58 
15. Wild type, but not kinase dead, EGFR stimulates Rac activation and  
        cell migration in response to EGF ..........................................................................60 
 
16. ErbB2 and EGFR are phosphorylated in EGFR-/- MCE kinase dead stable cells ......62 
17. PLCγ and PKC activation are not required for EGF stimulated Rac activation ........72 
18. Rac activation does not require PKCs .....................................................................74 
19. PI3K activity is required for Rac activation independent of Akt..............................77 
20. MEK 1/2 and ERK 1/2 activity are not required for Rac activation .........................79 
 vii 
21. Src family kinases are required for EGF stimulated Rac activation and migration ...81 
22. Reduced expression of Rac or Fyn inhibits Rac activation ......................................83 
23. PI3K and Src family kinases synergize to activate Rac ...........................................85 
24. EGF treatment of EGFR-/- MCE stable cells expressing EGFR tyrosine to 
phenylalanine mutations .........................................................................................87 
 
25. Migration of EGFR-/- MCE stable cells expressing EGFR tyrosine  
       to phenylalanine mutations......................................................................................89 
 viii 
LIST OF ABBREVIATIONS 
 
 
AR Amphiregulin 
BIM-1 Bisindolylmaleimide 1 
BTC Betacellulin 
C Carboxyl or Celsius 
DAG Diacylglycerol 
DH Dbl homology 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
EPR Epiregulin 
ERK 1/2 Extracellular signal-regulated kinase 1/2 
F Phenylalanine or Filamentous 
FACS Fluorescence activated cell sorter 
FAK Focal adhesion kinase 
FBS Fetal bovine serum 
FITC Fluorescein isothiocyanate 
Gab1 Grb2-associated binder-1 
GAP GTPase activating protein 
GDI Guanine nucleotide dissociation inhibitor 
GDP Guanosine diphosphate 
GEF Guanine nucleotide exchange factor 
Grb2 Growth factor receptor bound protein 2 
 ix 
GST Glutathione S transferase 
GTP Guanosine triphosphate 
HB-EGF Heparin binding epidermal growth factor 
HRP Horseradish peroxidase 
IFN Interferon 
IP3 Inositol 1, 4, 5-trisphosphate 
kDa Kilodalton 
MAPK Mitogen activated protein kinase 
MCE Mouse colon epithelial 
MEK 1/2 MAPK/ERK kinase 1/2 
N Amino 
NRG Neuregulin 
PAK p21 activated kinase 
PBD p21 binding domain 
PBS Phosphate buffered saline 
PE Phycoerythrin 
PH Pleckstrin homology 
PI3K Phosphoinositide 3-kinase 
PKC Protein kinase C 
PLC-γ Phospholipase C gamma  
PMA Phorbol 12-myristate 13-acetate 
PTB Phosphotyrosine binding 
PtdIns Phosphatidylinositol 
 x 
pY Phosphotyrosine 
RPMI Roswell Park Memorial Institute 
SH2 Src homology 2 
SH3 Src homology 3 
Shc Src homology collagen  
siRNA Small interfering ribonucleic acid 
Sos Son of sevenless 
SV40 Simian virus 40 
TGF-α Transforming growth factor alpha 
TM Transmembrane 
Y Tyrosine 
YAMC Young adult mouse colon 
 
 1 
CHAPTER I 
 
INTRODUCTION 
 
Biology of the intestinal epithelium 
In humans, the first line of defense against harmful pathogens is the innate 
immune response.  The most fundamental function of innate immunity is to provide a 
physical barrier that protects internal organs from being exposed to toxic substances.  For 
instance, the epithelial lining of the gastrointestinal tract is an important impenetrable 
barrier in animals that is constantly exposed to pathogenic bacteria and other potentially 
harmful substances.  Maintenance of this barrier is critical for normal growth, 
development, and disease prevention.  Unlike most tissues, the gastrointestinal tract has 
the ability to rapidly regenerate and repair damage.  The epithelial lining of the 
gastrointestinal tract consists of a single layer of columnar epithelial cells that are 
replaced every 4-5 days in humans.  This epithelial sheet forms a dynamic barrier that 
processes and absorbs nutrients from digested food while preventing ingestion of noxious 
substances present in the lumen of the gut.  The small and large intestine, which differ in 
their surface morphology, make up the largest part of the gastrointestinal tract.  The 
surface of the small intestine is covered with luminal protrusions, termed villi, and 
invaginations, termed crypts of Lieberkühn (Figure 1) (Reya and Clevers, 2005).  The 
villi function to increase the absorptive surface area of the small intestine, as most 
nutrient absorption occurs in this region (Sancho et al., 2004).  The large intestine, or  
 
Figure 1. Tissue anatomy of the small intestine. Putative stem cells (dark
blue) reside immediately above the Paneth cells (yellow) near the crypt
bottom. Proliferating progenitor cells occupy the remainder of the crypt.
Differentiated cells (green) populate the villus, and include goblet cells, 
enterocytes and enteroendocrine cells. From: Reya, T and Clevers, H.
Nature. 2005. 434: 843-850.
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colon, also contains crypts of Lieberkühn but has a flat surface epithelium devoid of villi 
(Figure 2A and 2B) (Reya and Clevers, 2005). 
A delicate balance of proliferation, migration, and apoptosis is required for 
maintenance of a healthy gastrointestinal tract.  Homeostasis is maintained as stem cells 
at the base of the crypts divide to give rise to proliferative progenitor cells (Figures 1 and 
Figure 2A) (Sancho et al., 2003).  These cells rapidly divide and begin to migrate out of 
the crypts towards the tip of the villus where they will take the place of old cells that are 
sloughed off into the lumen.  As these progenitor cells migrate up the crypts, they cease 
proliferation and commit to differentiate into one of three cell types: enteroendocrine, 
mucosecreting (Goblet), or absorptive (enterocyte) cells (Figures 1 and 2A).  Enterocytes, 
the main absorptive cell in the intestine, are the most abundant cell type, accounting for 
approximately 80% of the intestinal epithelial cells (de Santa Barbara et al., 2003).  
Goblet cells are found scattered from the mid-crypt to the tip of the villus.  These cells 
secrete mucus, which functions as an additional protective layer between the epithelium 
and the contents of the lumen (de Santa Barbara et al., 2003).  In the small intestine, some 
cells migrate into the base of the crypt and differentiate into a fourth cell type, Paneth 
cells (Figure 1) (Sancho et al., 2003).  After reaching the tip of the villus, the 
differentiated cells eventually undergo apoptosis and are shed into the lumen.   
Our understanding of the processes that maintain homeostasis of the 
gastrointestinal tract is continually evolving.  Defects in the regulation of proliferation, 
migration, or apoptosis result in a dysfunctional epithelium, which has been linked to the 
development of gastrointestinal disease and malignant transformation.  One category of 
gastrointestinal disease under intense investigation is inflammatory bowel disease, which  
Figure 2. Tissue anatomy of the colonic epithelium. A. Putative stem cells (dark blue) 
reside at the crypt bottom. Proliferating progenitor cells occupy two-thirds of the crypt. 
Differentiated cells (green) populate the remainder of the crypt and the flat surface 
epithelium. From: Reya, T and Clevers, H. Nature. 2005. 434:843-850. B. Hematoxylin
and eosin stain of colonic epithelium from an 8 week old SV129 mouse. Courtesy of
Jeremy Goettel, 2006.
A.
B. surface epithelium
crypts
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currently affects approximately 1 million people in North America (Bamias et al., 2005).  
Inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, are 
characterized by inflammation and epithelial cell damage in the intestine (Okamoto and 
Watanabe, 2005).  The pathogenesis of these diseases is not completely understood, 
although a number of genetic and environmental factors have been suggested to 
contribute to disease progression.  Inflammatory bowel diseases are thought to occur 
when the body mounts an inappropriate immune response to bacteria normally present in 
the lumen of the gut (Bamias et al., 2005).  Alternatively, defects in the barrier function 
of intestinal epithelial cells have also been implicated in the pathology of these diseases 
by allowing bacteria to penetrate the gastrointestinal tract, resulting in an inflammatory 
immune response (Podolsky, 2002).  Because the factors responsible for these diseases 
are not known, current therapeutic treatments include non-specific anti-inflammatory and 
immunosuppressive drugs to alleviate the inflammation.  Characterization of the 
molecular mechanisms underlying inflammatory bowel diseases is critical for the 
development of more specific therapeutic treatments.  As we learn more about the 
mechanisms that control the normal biological functions of these tissues, we also gain 
insight into how these pathways may be deregulated in diseases.  
 
Wound healing in the intestine 
Harmful substances present in the lumen of the gut continually challenge the 
integrity of the intestinal epithelium, sometimes resulting in cell damage (Figure 3A and 
3B). In response to injury, intestinal epithelial cells initiate a wound repair process that 
can be divided into two distinct phases.  Immediately following injury, epithelial cells  
Figure 3. Restitution in the small intestine. A. Normal small intestinal epithelium. 
B. Damaged epithelial cells detach from the the tip of villus exposing the underlying
basal lamina to the luminal contents. C. Epithelial cells surrounding the wound begin 
to migrate to cover the denuded area. D. Restitution is completed as epithelial cells 
close the wound, restoring the epithelium. Adapted from: Reya and Clevers, 2000. 
A. B.
C. D.
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surrounding the wound lose their polarity, taking on a flattened morphology, and rapidly 
migrate into the denuded area to restore the epithelial barrier (Figure 3C and 3D) (Feil et 
al., 1989) (Argenzio et al., 1988).  This process, termed “restitution”, has been shown to 
occur rapidly in in vivo models of injury, with complete re-epithelialization occurring as 
quickly as a few minutes after wounding, depending on the size of the injured area (Lacy, 
1988).  In vivo and in vitro models of intestinal injury have demonstrated that the first 
visible sign of restitution is the extension of lamellipodia over the denuded basal lamina 
(Feil et al., 1987) (Feil et al., 1989).  In both the small and the large intestine, enterocytes 
were the only cell type observed migrating over the basal lamina, suggesting that only 
these cells contribute to the wound healing response (Lacy, 1988).  After flattened 
epithelial cells completely cover the wound, these cells begin to regain their columnar 
shape and eventually return to polarized epithelial cells (Argenzio et al., 1988).   
The second phase of wound healing, termed “regeneration”, completes the 
process of wound repair (Okamoto and Watanabe, 2005).  During this phase, 
proliferation is stimulated in crypts near the damaged mucosa to re-populate the 
epithelium.  This process occurs over a much longer period of time as cells must undergo 
mitosis in the base of the crypts, followed by differentiation and migration up the crypt-
villus axis (Okamoto and Watanabe, 2005).  Alterations in either phase of the wound 
healing response are thought to contribute to chronic gastrointestinal diseases, such as 
inflammatory bowel disease (Bamias et al., 2005).   
Rapid restitution is a critical part of maintaining a protective barrier in the 
gastrointestinal tract because slow or impaired restitution exposes the organism to 
harmful substances in the lumen.  Much work has focused on trying to understand how 
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soluble factors present in the lumen contribute to restitution.  A number of growth 
factors, including transforming growth factor α (TGF-α) and epidermal growth factor 
(EGF) (Riegler et al., 1996) (Wilson and Gibson, 1999), as well as trefoil factor peptides 
(Dignass et al., 1994) and transforming growth factor β (Dignass and Podolsky, 1993) 
accelerate restitution in in vitro models of intestinal injury.  However, the molecular 
mechanisms by which these factors activate intestinal epithelial cell migration are poorly 
defined.  Several of these factors are currently being tested in clinical trials as therapeutic 
treatments for inflammatory bowel diseases, of which the most promising so far is EGF. 
Administration of EGF-containing enemas to patients with ulcerative colitis in 
combination with the anti-inflammatory drug mesalamine induced remission in 10 out of 
12 patients compared to only 1 out of 12 in patients receiving mesalamine only (Sinha et 
al., 2003).  While larger studies are necessary to confirm the efficacy of EGF treatment 
for ulcerative colitis, this study demonstrates that data obtained from in vitro models of 
intestinal injury can be successfully applied to therapeutic treatments.  
 
Cell migration and Rho GTPases 
The process of cell migration is critical throughout the human life cycle (reviewed 
in (Horwitz and Webb, 2003)).  In the adult, cell migration is required for homeostasis of 
the gastrointestinal tract as cells continually migrate up the crypt-villus axis.  In humans, 
deregulated cell motility can cause pathologic conditions both when migratory cells 
become non-motile and when non-migratory cells aberrantly start to move.  For example, 
when cancerous cells become migratory, they stray from the primary tumor, and can 
eventually move throughout the body to create secondary tumors.  In contrast, defects in 
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intestinal epithelial cell migration during restitution contribute to an inability to heal 
ulcerations, perpetuating chronic intestinal diseases described above.  Because it is a 
fundamental process throughout life, much work has focused on identifying the 
mechanisms that control cell migration.   
The actin cytoskeleton consists of bundles and networks of actin filaments that 
provide the physical structure for cell shape and allow the capacity for cell migration 
through dynamic remodeling of actin filaments.  Successful cell migration requires 
several phases of coordinated actin rearrangement.  In response to an external migratory 
stimulus, a cell must first establish a direction of movement and then begin to polarize 
creating a front, termed the leading edge, and a rear, termed the trailing edge (Figure 4A) 
(reviewed in (Raftopoulou and Hall, 2004)).  Actin polymerization and filament 
elongation at the leading edge create broad actin-rich membrane protrusions, called 
lamellipodia, which extend in the direction of movement.  New sites of adhesion are then 
established to anchor the leading edge to the substratum (Figure 4B) (Ridley et al., 2003).  
Actin:myosin filament contractions at the rear of the cell move the cell body forward and 
cell adhesions at the rear are released, resulting in a net forward movement (Figure 4C).   
 The process of cell migration requires tight regulation of the actin cytoskeleton, 
which is controlled by members of the Rho family of small GTPases (reviewed in 
(Raftopoulou and Hall, 2004)).  Rho GTPases are a distinct subfamily of the Ras family 
of small GTPases, named for their relatively small protein size of approximately 21 kDa.  
Currently 22 mammalian Rho GTPases have been identified and shown to regulate actin-
dependent processes in all eukaryotic cells (reviewed in (Rossman et al., 2005) and (Jaffe 
and Hall, 2005)).  Rho GTPases cycle between an active GTP-bound state and an inactive  
Figure 4. Cell migration. A. Upon sensing a migratory stimulus, the cell establishes
a direction of migration. B. The cell extends lamellipodial protrusions in the 
direction of migration, forms new adhesions with the substratum, and stress fibers
begin to form. C. Actin:myosin contraction pulls the cell body forward, adhesions
at the rear release and the trailing edge begins to retract. 
B.
A. Direction of migration
C.
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GDP-bound state (Figure 5). Three classes of regulatory proteins regulate this cycling 
both spatially and temporally.  Guanine nucleotide dissociation inhibitors (GDIs) bind to 
and sequester inactive Rho GTPases in the cytoplasm.  When stimulated, Rho-GTPases 
are released from the GDI, exposing a C-terminal prenylation, which translocates the 
small GTPases to the plasma membrane (Figure 5) (reviewed in (Seabra, 1998) and 
(Rossman et al., 2005)).  Guanine nucleotide exchange factors (GEFs) catalyze the 
exchange of GDP for GTP to activate Rho GTPases at the plasma membrane.  Active 
Rho GTPases initiate signaling through downstream effector proteins that specifically 
recognize and bind to the GTP-bound form of the GTPase.  GTPase activating proteins 
(GAPs) stimulate the intrinsic GTPase activity to inactivate the GTPase, completing the 
cycle. 
In an effort to identify a biological function for the Rho GTPases, work from the 
laboratory of Dr. Alan Hall in the 1990s revealed that three family members, Rac, Rho, 
and Cdc42, control individual elements of actin cytoskeletal rearrangement.  
Microinjection of constitutively active Rho into serum starved confluent Swiss 3T3 cells 
rapidly induced a dramatic reorganization of the actin cytoskeleton, activating the 
formation of dense microfilament networks, or stress fibers (Paterson et al., 1990).  This 
study provided the first direct evidence that Rho is involved in regulating the 
organization of polymerized actin.  Further experiments demonstrated that serum 
stimulation of quiescent cells induced the rapid formation of actin stress fibers, a 
phenotype similar to the injection of constitutively active Rho (Ridley and Hall, 1992). 
Treatment of cells with individual components of serum confirmed that growth factors 
alone produced similar effects.  Further studies of the Rho family of GTPases revealed  
Figure 5. Regulation of Rho GTPases. Inactive GDP-bound Rho GTPases are
sequestered in the cytoplasm by GDIs, which mask the c-terminal prenylation. 
Release of the GDI allows the GTPase to translocate to the plasma membrane.
GEF activation catalyzes the exchange of GDP for GTP, activating the GTPase.
The active GTPase binds to downstream effectors, which specifically recognize 
the GTP-bound form.  GAPs stimulate intrinsic GTPase activity, inactivating
the GTPase.
GDI Rho
GTPase
GDP
Rho
GTPase
GDP
Pi
GDP
GTP
Effector
Rho
GTPase
GTP
GEF
GAP
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that microinjection of fibroblasts with wild type Rac induced an accumulation of actin-
rich membrane ruffles at the cell periphery.  This effect was enhanced by microinjection 
of constitutively active Rac and reversed by a Rac mutant in which a conserved threonine 
essential for activity was mutated to alanine (Ridley et al., 1992).  Similar microinjection 
experiments with Cdc42 a few years later demonstrated that activation of Cdc42 results 
in the formation of spike-like filopodial extensions at the cell periphery (Nobes and Hall, 
1995).  An analysis of Rac, Rho, and Cdc42 activity in scrape-wound assays 
demonstrated that coordinated activation of these GTPases regulates processes required 
for cell migration.  Cdc42 activity controls the extension of filopodia, which determines 
the direction of cell migration and is involved in the establishment of polarity.  The 
extension of lamellipodia in the direction of movement is regulated by Rac activation, 
followed by contraction of the cell body mediated by Rho activation (Nobes and Hall, 
1999).  These studies established a basic paradigm for the control of cell migration by the 
Rho GTPases.   
As rapid cell migration is critical for proper restitution in the gastrointestinal tract, 
the Rho GTPases are most likely required for proper intestinal epithelial wound healing.  
However, little is known about the requirement for Rho GTPases in restitution in vivo.  
Work in cultured intestinal epithelial cells has demonstrated that inhibition of Rho 
significantly reduces basal migration and completely blocks EGF induced migration in a 
scratch wound assay, suggesting that Rho may be involved in maintenance of the 
intestinal epithelium and restitution in vivo (Santos et al., 1997).  While work in cultured 
fibroblasts has demonstrated that Rac is involved in wound closure, no work has been 
done in cultured intestinal epithelial cells to study the potential role of Rac in the process 
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of restitution.  The Rac family consists of three different genes, Rac1, Rac2, and Rac3.  
While Rac1 is ubiquitously expressed, Rac2 is hematopoietic specific and Rac3 is 
expressed only in the nervous system.  Rac1 deficient mice die at embryonic day 9.5 as a 
result of severe developmental defects (Sugihara et al., 1998).  In contrast, mice with a 
targeted deletion of Rac2 or Rac3 are viable with no obvious phenotype.  Because Rac1 
null mice are not viable, a chimeric mouse expressing dominant negative Rac1 in the 
small intestine was generated to investigate the in vivo function of Rac1 in the intestinal 
epithelium.  In these mice enterocyte migration along the crypt-villus axis is significantly 
reduced and epithelial cell differentiation is inhibited, demonstrating that Rac1 GTPase 
activity is required for intestinal epithelial homeostasis (Stappenbeck and Gordon, 2000).  
However, the signaling mechanisms that regulate the activation of Rac in the intestine 
have not been defined and more work is necessary to understand the role of this GTPase 
in intestinal epithelial cell migration. 
 
ErbB family of receptor tyrosine kinases 
 Growth factor stimulation of cultured fibroblasts induces a dramatic 
rearrangement of the actin cytoskeleton (Ridley and Hall, 1992) and induces cell 
proliferation (Carpenter and Cohen, 1976).  Soluble growth factors bind to receptor 
tyrosine kinases, which transmit signals from the extracellular milieu to the inside of the 
cells.  Receptor tyrosine kinases are characterized by an extracellular ligand binding 
domain, a single pass transmembrane domain, and a cytoplasmic portion containing a 
conserved protein tyrosine kinase domain as well as multiple potential sites of tyrosine 
autophosphorylation (Schlessinger, 2000).  In response to ligand binding, the receptors 
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dimerize and trans-autophosphorylate on tyrosine residues, which initiates downstream 
signaling cascades.  The ErbB family of receptor tyrosine kinases consists of four closely 
related members: ErbB1, ErbB2, ErbB3, and ErbB4.  The founding member of this 
family, ErbB1, better known as the epidermal growth factor receptor (EGFR), was 
identified by Dr. Stanley Cohen and co-workers in their search to identify the receptor 
that bound epidermal growth factor (EGF) (Cohen et al., 1982) (Buhrow et al., 1982).  
Soon after Cohen’s discovery of the first receptor protein tyrosine kinase, EGFR was 
identified as the cellular homolog of the v-erbB oncogene and was subsequently 
designated ErbB1 (Downward et al., 1984b) (Ullrich et al., 1984).  
 ErbB receptor tyrosine kinases are activated by the EGF family of ligands, which 
consists of over 10 structurally related polypeptides, including several alternatively 
spliced variants.  In response to ligand binding, ErbB receptors form homo- or 
heterodimers, depending on the ligand specificity and availability of other family 
members for dimerization (Figure 6A).  EGF family ligands are characterized by an EGF-
like domain that contains six spatially conserved cysteine residues (Groenen et al., 1994).  
These conserved cysteines form three disulfide-bonded intramolecular loops required for 
biological activity of these polypeptides (Kumar and Vadlamudi, 2000).  EGF ligands are 
synthesized as active, transmembrane precursors, which can signal through a juxtacrine 
pathway (Massague and Pandiella, 1993).  Cell-surface proteases cleave the extracellular 
domain to release a soluble form of the active ligand (Harris et al., 2003).  Although the 
EGF family of ligands share considerable sequence identity in their EGF-like domains, 
ErbB receptor binding affinity is highly variable (Jones et al., 1999).  EGF, transforming 
growth factor α (TGF-α), and amphiregulin (AR) bind specifically to ErbB1 (EGFR),  
B.
Figure 6. Structure of ErbB receptors and model of activation. A. Structure of ErbB
receptors. Extracellular domains I-IV are indicated, followed by a short transmembrane 
domain (TM), the intracellular tyrosine kinase domain, and the c-terminal tail containing
multiple phosphorylation sites. Binding specificity of the EGF family ligands is shown 
at the top. The inactive ligand binding domains of ErbB2 and inactive kinase domain of 
ErbB3 are marked with an X. B. Proposed model of ErbB activation. A 130o rotation of
the tethered monomer  allows ligand binding and dimerization to occur. From: Burgess, 
A.W., et. al., Molecular Cell. 2003. 12: 541-552.
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while betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (ER) bind to 
both ErbB1 and ErbB4 (Figure 6A) (Holbro and Hynes, 2004).  The neuregulins (NRG) 
can be divided into two subclasses based on their binding affinity: NRG-1 and NRG-2  
bind to ErbB3 and ErbB4, while NRG-3 and NRG-4 only bind ErbB4 (Figure 6A) 
(Holbro and Hynes, 2004).  Investigation of EGF ligands has greatly expanded this field  
in the years since the identification of EGF, the founding member of this family (Cohen, 
1962) (Cohen, 1964); however, no ligand has been identified for ErbB2, making this the 
only orphan receptor in the ErbB family.   
Recent reports of the crystal structure of the ErbB receptors has shed light onto 
the mechanism of receptor activation, and the culmination of this work has led to a 
comprehensive model for ligand binding and dimerization (Figure 6B).  Crystallographic 
studies have revealed that in the absence of ligand ErbB receptors exist in an inactive, 
monomeric state (reviewed in (Burgess et al., 2003).  Intramolecular interactions between 
extracellular domains II and IV prevent the formation of a ligand binding pocket between 
domains I and III.  In the presence of ligand, domains I and II rotate 130o, creating a high 
affinity binding pocket between domains I and III (Figure 6B).  In the extended 
monomer, each receptor molecule binds to a single ligand molecule, stabilizing the active 
conformation.  This conformational change exposes a dimerization arm, previously 
hidden by the domain II/IV tether that allows the receptor to participate in intermolecular 
interactions with other ErbB receptors (Burgess et al., 2003).  While this model agrees 
with all of the available data for EGFR, ErbB3, and ErbB4, this paradigm does not apply 
to ErbB2.  The crystal structure for ErbB2 has revealed that this receptor exists in an 
active conformation with an extended dimerization arm in the absence of ligand, 
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explaining why this receptor is the preferred dimerization partner for the other ErbB 
family members (Garrett et al., 2003).   
While the four ErbB receptors share considerable sequence homology, their 
biological functions are not redundant.  In transgenic mice, individual null mutations for 
any of the ErbB genes results in embryonic lethality, demonstrating that each of these 
receptors is required for mammalian development (reviewed in (Olayioye et al., 2000)).  
A closer look at the amino acid sequences of the ErbB receptors reveals several other 
differences that result in divergent biological functions.  Variable residues in the 
extracellular domain of ErbB2 alter the 3-dimensional structure of this domain, making it 
unable to bind ligand.  Three of the seven conserved residues involved in stabilizing the 
intramolecular tether in the other ErbB family members are different in ErbB2 (Garrett et 
al., 2003).  While these amino acids substitutions allow the extracellular domain of 
ErbB2 to constitutively form an extended conformation, they also create a domain I/III 
pocket that mimics the presence of ligand, making it difficult for ligand to bind (Garrett 
et al., 2003).  Furthermore, several amino acids required for ligand binding in the other 
ErbBs are not conserved in ErbB2 (Met 10, Arg13, and Pro15), further distinguishing the 
extracellular domain of ErbB2 from the conserved ectodomains of ErbB1, ErbB3, and 
ErbB4 (Roskoski, 2004a).   
Although the kinase domain of ErbB3 is highly homologous to the other family 
members, kinase activity is impaired in this receptor (Guy et al., 1994).  In ErbB3 the 
conserved protein tyrosine kinase catalytic loop amino acids HRDLAARN found in 
EGFR, ErbB2, and ErbB4 are altered to HRNLAARN (Plowman et al., 1990).  This 
conserved aspartic acid forms the catalytic base required for phosphotransfer, and 
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substitution of this base with asparagine yields a catalytically inactive kinase.  As a result, 
ErbB3 homodimers are unable to trans-autophosphorylate, forming an inactive dimer.  
Activation of ErbB3 occurs through heterodimerization with other ErbB family members. 
The ErbB family of receptors and their ligands constitutes a highly complex 
signaling network with multiple input layers that regulates diverse biological outcomes 
from embryogenesis through adulthood (reviewed in (Yarden and Sliwkowski, 2001)).  
The availability and specificity of the numerous ligands provides the first layer of 
complexity, followed by the capacity of these receptors to form different combinations of 
homo- and heterodimers.  Activation of downstream signaling pathways results from 
trans-autophosphorylation of the ErbB receptors on C-terminal tyrosine residues, which 
create docking sites for signaling proteins with Src-homology 2 (SH2) and 
phosphotyrosine-binding (PTB) domains.  The amino acid sequences surrounding the C-
terminal phosphorylated tyrosines create specificity for different signaling molecules (see 
below) (Songyang et al., 1993) (Uhlik et al., 2005). Some of these recruited proteins 
require phosphorylation by ErbB kinases for their activation, such as Shc (Pronk et al., 
1994).  The ErbB family contains both redundant and unique phosphotyrosine sequences 
in their C-terminus.  For example, all of the ErbB receptors couple to the mitogen 
activated protein kinase (MAPK) cascade through Shc binding, while only ErbB3 and 
ErbB4 possess direct binding sites for the p85 subunit of phosphoinositide 3-kinase 
(PI3K) (reviewed in (Olayioye et al., 2000)).   
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Signaling through epidermal growth factor receptor 
Initial studies by Dr. Stanley Cohen provided the first glimpse of EGFR 
biological activity by demonstrating that EGF stimulated increased levels of 
phosphotyrosine in A431 cells (Ushiro and Cohen, 1980).  In the years since, much work 
has focused on identifying the signaling pathways that are activated by EGFR.  
Specificity for downstream signaling is determined by the tyrosine residues trans-
autophosphorylated in the C-terminal tail, and while a clear requirement has emerged for 
several consensus tyrosines, the importance of other residues is still under investigation.  
Unlike platelet derived growth factor receptor, in which specific tyrosine residues are 
required for different downstream signaling pathways, the autophosphorylation sites of 
EGFR have redundant binding partners and can become compensatory in the absence of 
other sites, making mutational analyses difficult to interpret (Soler et al., 1994).  This 
work is also complicated by the ability of this receptor to heterodimerize with the other 
ErbBs, making it difficult to establish which pathways are specific to activation of EGFR. 
A further complicating factor is that the Src family of tyrosine kinases has been shown to 
phosphorylate EGFR on conflicting tyrosine residues and the importance of these 
phosphorylation events is not yet known.  However, treatment of cells with ligands that 
preferentially activate EGFR (EGF, amphiregulin, and TGF-α) has revealed a number of 
signaling molecules that are direct targets of EGFR activation. While a clear model for 
EGFR activation has recently emerged, the complex signaling pathways and functional 
consequences downstream of the receptor are still being elucidated.  
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Autophosphorylation sites 
The identification of phosphorylated tyrosine residues and their corresponding 
binding partners has provided important insight into the mechanism by which EGFR 
elicits downstream biological effects.  Initial phosphopeptide mapping studies of EGFR 
identified tyrosines 1068, 1148, and 1173 as in vitro sites of autophosphorylation, all of 
which are in the C-terminal tail (Downward et al., 1984a).  In vivo labeling of A431 cells 
confirmed that these tyrosines were phosphorylated in response to EGF treatment, with 
tyrosine 1173 being the major site of tyrosine phosphorylation in vivo (Downward et al., 
1984a).  Further phosphopeptide mapping studies identified additional sites of 
phosphorylation at tyrosine 1086 and tyrosine 992 both in vitro and in intact cells 
(Margolis et al., 1989b) (Walton et al., 1990).  Since the discovery of tyrosines 1068, 
1148, and 1173 as the major sites of EGFR autophosphorylation and tyrosines 992 and 
1086 as minor autophosphorylation sites, much work has focused on the identification of 
binding partners and signaling pathways downstream of receptor activation and this is 
still an ongoing area of investigation (Figure 7).   
 
Activation of the mitogen activated protein kinase cascade 
All ErbB receptors activate the mitogen activated protein kinase (MAPK) 
pathway either directly through Grb2 or indirectly through the adaptor protein Shc.  In 
unstimulated cells, Grb2 constitutively associates with proline rich sequences in Sos, the 
guanine nucleotide exchange factor for Ras, through both of its SH3 domains (Li et al., 
1993) (Egan et al., 1993).  Upon EGF stimulation, the Grb2/Sos complex is recruited to 
EGFR through direct binding of the Grb2 SH2 domain to phosphorylated tyrosine  
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Figure 7. Structure of EGFR. The extracellular ligand binding domain is in an inactive
conformation. The intracellular kinase domain (green) does not contain any auto-
phosphorylation sites.  Autophosphorylation sites (black), their binding partners, and 
downstream targets are shown.  Src phosphorylation sites are shown to the left (blue).
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residues on the receptor (Rozakis-Adcock et al., 1993).  When recruited to the membrane 
via Grb2, Sos stimulates the exchange of GDP for GTP on Ras.  Activated GTP-bound 
Ras initiates the MAPK cascade through binding and activating Raf kinase, which 
phosphorylates MEK1/2 on serine residues.  MEK1/2, a dual specificity kinase,  
phosphorylates ERK1/2 on tyrosine and threonine residues, targeting it to the nucleus 
where it phosphorylates and activates a number of transcription factors involved in 
proliferation.   
EGFR has been shown to activate the MAPK cascade through each of its major 
autophosphorylation sites.  Tyrosine to phenylalanine (Y-F) mutational analysis of EGFR 
revealed that phosphorylation of tyrosines 1068 and 1086 creates high affinity binding 
sites for the SH2 domain of Grb2 (Okutani et al., 1994). Alternatively, EGFR can recruit 
Grb2 indirectly through the adaptor protein Shc.  In response to growth factor 
stimulation, Shc binds to EGFR and is tyrosine phosphorylated (Pelicci et al., 1992).  
Grb2 binds to phosphorylated Shc proteins through its SH2 domain and this recruitment 
of Grb2/Sos activates the Ras/MAPK pathway (Rozakis-Adcock et al., 1992).  EGFR Y-
F mutational analysis demonstrated that Shc binds with high affinity to phosphotyrosine 
1148, and to a lesser extent with phosphotyrosine 1173 (Okabayashi et al., 1994).  
Mutation of both of these tyrosines abolished most of the Shc binding, however, tyrosine 
992 was found to exhibit some compensatory Shc binding in the absence of the other two 
tyrosines, suggesting that this is not a major site of Shc recruitment.  Further analysis 
revealed that the PTB domain of Shc is required for its interaction with tyrosine 1148, 
and its SH2 domain mediates interaction with tyrosine 1773, which may explain the 
differences in binding affinity (Sakaguchi et al., 1998).  
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Activation of phosphoinositide 3-kinase 
Another signaling pathway activated by all members of the ErbB family is 
phosphoinositide 3-kinase (PI3K).  The PI3K superfamily is made up of a large family of 
enzymes that all phosphorylate the 3’ hydroxyl group of phosphatidylinositol (PtdIns). 
However, they differ in their substrate specificity, mechanism of regulation, and subunit 
composition (reviewed in (Foster et al., 2003)).  Class IA PI3Ks are heterodimeric 
enzymes that consist of a p85 regulatory subunit and a p110 catalytic subunit.  The p85 
subunit contains two SH2 domains, which have been shown to bind with high affinity to 
the sequence pYXXM (Songyang et al., 1993).  The p110 subunit contains a stretch of 
100 amino acids at its N-terminus that constitutively binds to the p85 subunit.  In vivo, 
the class I PI3Ks selectively phosphorylate PtdIns 4,5-bisphosphate (PtdIns-4,5-P2), but 
they are capable of phosphorylating PtdIns, PtdIns 4-phosphate (PtdIns-4-P), and PtdIns-
4,5-P2 in vitro.   
Class IA PI3Ks are activated in response to growth factor stimulation through 
binding of p85 SH2 domains to phosphorylated receptors.  Binding of the p85 subunit to 
phosphorylated tyrosines increases the catalytic activity of the p110 subunit 2-3 fold 
(Carpenter et al., 1993) and also positions PI3K in close proximity with its substrates in 
the plasma membrane.  In resting cells, PtdIns-4-P and PtdIns-4,5-P2 account for 90% of 
the phosphoinositide in the plasma membrane.  Activation of PI3K generates a rapid and 
transient increase in the levels of PtdIns-3,4-P2 and PtdIns-3,4,5-P3 in the plasma 
membrane at the sites of PI3K recruitment.  The generation of these lipid products 
recruits proteins with lipid binding domains, such as pleckstrin homology (PH) or FYVE 
domains, to the plasma membrane (Rameh and Cantley, 1999).  One class of proteins that 
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contain a phospholipid binding domain are the guanine nucleotide exchange factors 
(GEFs) for the Rho family of GTPases.  Over 60 mammalian GEFs have been identified, 
most of which contain a characteristic tandem PH domain and Dbl homology (DH) 
domain (Rossman et al., 2005).  While the DH domain is critical for nucleotide exchange, 
the PH domain is thought to contribute to GEF activation by recruiting it to the plasma 
membrane in response to PI3K activity.  However, other factors are required for full GEF 
activation as PH domain membrane recruitment is not sufficient for activation (Welch et 
al., 2003). 
The best-characterized target downstream of PI3K is the serine/threonine kinase 
Akt.  In response to PI3K activation, the N-terminal PH domain of Akt binds with high 
affinity to PtdIns-3,4-P2, recruiting it to the plasma membrane (Franke et al., 1997).  
Another serine/threonine kinase, phosphoinositide-dependent kinase-1 (PDK-1), is also 
recruited to the membrane through binding of its PH domain to PtdIns-3,4,5-P3.  PDK1 is 
a constitutively active kinase that has been shown to phosphorylate Akt on threonine 308 
in response to PI3K activation (Stephens et al., 1998).  Full activation of Akt requires 
phosphorylation on threonine 308 by PDK1 and on serine 473 by an unknown kinase 
(Alessi et al., 1996).  When activated, Akt promotes cell survival through a number of 
different pathways, including phosphorylation and inactivation of a number of pro-
apoptotic proteins, such as BAD (reviewed in (Song et al., 2005)).  Because a large 
number of proteins contain phospholipid binding domains, PI3K activation contributes to 
activation of many different signaling pathways in addition to cell survival.  
Interestingly, activation of PI3K in response to EGF treatment has been reported 
despite the lack of p85 consensus binding sites in EGFR (Bjorge et al., 1990).  Mutational 
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analysis of EGFR revealed that the SH2 domain of the p85 subunit of PI3K does not bind 
with high affinity to any of the autophosphorylation sites (Soler et al., 1994).  An adaptor 
protein, called Grb2-associated binder-1 (Gab1), provided the missing link for the 
mechanism of PI3K activation by EGFR.  Gab1 binds to the SH3 domain of Grb2, 
becomes tyrosine phosphorylated in response to EGF treatment, and contains three 
binding sites for the SH2 domains of p85 (YXXM motifs) (Holgado-Madruga et al., 
1996).  Gab1 association with EGFR requires tyrosines 1068 and 1086 (Rodrigues et al., 
2000), as well as the SH3 domain of Grb2 (Lock et al., 2000), suggesting that Gab1 binds 
to EGFR indirectly through association with Grb2.  A recent study demonstrates that 
EGF treatment does not stimulate Akt activation in Gab1 null fibroblasts, but expression 
of Gab1 in the same null cells restores EGF stimulated Akt activation (Mattoon et al., 
2004).  These studies suggest that both Grb2 and Gab1 are essential for activation of 
PI3K by EGFR; however, this paradigm is still under investigation. 
 
Activation of phospholipase Cγ 
Initial studies investigating the physiological substrates of EGFR discovered that 
phosphotyrosine proteins isolated from EGF treated A431 cells exhibited phospholipase 
C activity (Wahl et al., 1988).  Phospholipase Cγ (PLCγ) was soon identified as a 
substrate for EGFR tyrosine kinase (Meisenhelder et al., 1989) (Margolis et al., 1989a).  
In response to EGFR activation, PLCγ1 binds to phosphorylated tyrosines 992 and 1173, 
with highest affinity to tyrosine 1173, through its SH2 domains (Rotin et al., 1992) 
(Chattopadhyay et al., 1999).  Recruitment of PLCγ1 to the activated receptor results in 
its tyrosine phosphorylation, a requirement for its activation (reviewed in (Carpenter and 
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Ji, 1999)).  Activated PLCγ1 hydrolyzes PtdIns-4,5-P2 to generate the second messengers 
diacylglycerol and inositol trisphosphate (IP3). Binding of IP3 to receptors on the 
endoplasmic reticulum stimulates the release of calcium pools, resulting in increased 
intracellular calcium concentrations.  Diacylglycerol, in combination with increased 
calcium levels, activates the protein kinase C family of serine threonine kinases, which in 
turn phosphorylate and activate numerous signaling proteins.  The exact biological 
consequences of PLCγ activation in response to EGF have been difficult to identify 
because numerous calcium-dependent and PKC dependent pathways are turned on in 
response to diacylglycerol and IP3 production.  Previous work from our lab, as well as 
others, has demonstrated that phospholipase C (PLC) activity is required for EGF 
stimulated cell migration (Chen et al., 1994b) (Polk, 1998).  However, the mechanism by 
which PLC contributes to EGF stimulated migration is still not clear.  We have 
demonstrated that activation of PKCs downstream of PLC is required for EGF stimulated 
migration (Polk, 1998), while studies by a different group suggested that PLC activates 
the small GTPase Cdc42 to promote directed cell migration in response to EGF (Chou et 
al., 2003). 
 
Receptor internalization and degradation 
Increased activation or expression of EGFR has been detected in many different 
cancers and correlates with poor prognosis, suggesting that constitutive signaling through 
EGFR is deleterious to cells (reviewed in (Pal and Pegram, 2005).  In untransformed 
cells, EGFR signaling is attenuated by the rapid endocytosis and subsequent degradation 
of this receptor in response to ligand binding (reviewed in (Wiley, 2003)).  Unlike the 
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other ErbB receptors, which remain at the cell surface after ligand binding, EGFR is 
internalized through clathrin-coated pits within minutes of ligand stimulation and binds to 
the clathrin associated protein complex AP-2 (Baulida et al., 1996).  Two internalization 
motifs, FYRAL at 973-977 and QQGFF at 996-100, were discovered in the C-terminal 
tail of EGFR that are not found in the other ErbBs (Chang et al., 1993).  Mutation of 
tyrosine 974 in the FYRAL sequence to phenylalanine blocks AP-2 binding and slows 
ligand-stimulated internalization (Sorkin et al., 1996); however, phosphorylation of this 
tyrosine residue has not been demonstrated and is not required for AP-2 binding.   
Activation of EGFR in response to ligand binding, but not the other ErbB family 
members, stimulates phosphorylation of the E3 ubiquitin ligase c-Cbl (Levkowitz et al., 
1996). Cbl binds to phosphotyrosine 1045 of EGFR, a previously unidentified 
autophosphorylation site, stimulating EGFR ubiquitination and subsequent degradation 
(Levkowitz et al., 1999).  The exact requirement for c-Cbl activity in EGFR trafficking is 
still under intense investigation as this study conflicts with a previous report in which a 
C-terminal truncation mutant (1-1022) lacking tyrosine 1045 did not exhibit impaired 
degradation in response to ligand (Wiley et al., 1991).  Interestingly, a recent study 
demonstrated that EGFR mutations found in non-small-cell-lung cancers exhibited a 
specific increase in phosphorylation of tyrosine 1045 in response to EGF (Chen et al., 
2005) suggesting a potential role for this autophosphorylation site and subsequent c-Cbl 
activation in carcinogenesis. 
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Activation of Src family kinases 
EGFR activation stimulates increased tyrosine phosphorylation of a number of 
proteins, some of which are direct targets of EGFR kinase activity, and others which are 
substrates for the Src family kinases.  These nonreceptor tyrosine kinases share a highly 
conserved structure consisting of an SH3 domain, followed by an SH2 domain, a kinase 
domain, and a C-terminal inhibitory tyrosine (Y527) (reviewed in (Roskoski, 2004b)).  In 
the inactive conformation, the SH2 domain of Src binds to phosphorylated tyrosine 527, 
creating an intramolecular inhibition of its kinase activity.  Dephosphorylation of tyrosine 
527 relieves this inhibition and exposes another highly conserved residue in the activation 
loop of the kinase, tyrosine 416.  Subsequent autophosphorylation of tyrosine 416 greatly 
enhances Src kinase activity (reviewed in (Roskoski, 2005)).  Alternatively, Src can be 
activated when phosphorylated tyrosine residues on other proteins bind to its SH2 
domain, displacing the intramolecular inhibition and opening the conformation of the 
kinase.  Unlike the receptor tyrosine kinases, which are anchored in the plasma 
membrane, the Src family kinases are targeted to the membrane by an N-terminal 
myristoylation sequence, positioning these kinases in close proximity with 
transmembrane receptors.  Src family kinases are involved in signal transduction 
downstream of a broad range of cell surface receptors, including integrins, G-protein 
coupled receptors, and growth factor receptors. The Src family consists of 11 members in 
humans, three of which, Src, Yes and Fyn, are ubiquitously expressed.  The remaining 
family members exhibit a more restricted pattern of expression, many of which are 
specific to hematopoietic cells.  The characteristic functional domains and regulatory 
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properties of the Src family kinases are conserved in many other tyrosine kinases, making 
Src a prototype for the study of other tyrosine kinases. 
Overexpression of both Src and EGFR has been reported in several different 
human tumors, suggesting that these kinases synergize to promote tumor formation 
(reviewed in (Biscardi et al., 1999b)).  Despite intense investigation, the exact nature of 
the relationship between these two kinases is unclear.  In cells engineered to overexpress 
both EGFR and Src at very high levels, two novel EGFR phosphopeptides were 
observed, which were predicted to be sites of Src phosphorylation (Maa et al., 1995).  
Phosphopeptide mapping identified tyrosines 845 and 1101 as the residues 
phosphorylated in vitro and in vivo in response to EGF in these cells, but these sites could 
not be detected in cells expressing endogenous levels of these kinases (Biscardi et al., 
1999a). Tyrosines 891 and 920 were also identified as sites of Src phosphorylation 
(Stover et al., 1995).  Phosphorylation of tyrosine 920 creates a high affinity binding site 
for the SH2 domain of p85, and both tyrosine 891 and 920 are predicted to bind to the 
SH2 domain of Src with high affinity (Stover et al., 1995).  However, several other labs 
have not detected any of these sites in their phosphopeptide mapping studies.  While the 
reason for this discrepancy is unclear, one possibility is that cell type specificity 
determines the requirement for Src phosphorylation.  In vivo phosphopeptide mapping 
studies identifying the autophosphorylation sites were generated either from A431 cells, a 
human epidermoid carcinoma cell line that overexpresses EGFR to very high levels 
(Downward et al., 1984a) (Hsuan et al., 1989), or cells transfected with human EGFR 
(Margolis et al., 1989b) (Walton et al., 1990).  In these cell lines, autophosphorylation 
may be favored due to the low availability of endogenous Src molecules per receptor.   
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The studies of Stover, et. al., which identified tyrosines 891 and 920 as in vivo Src 
phosphorylation sites were performed in breast and colorectal cancer cell lines, which 
may overexpress both Src and EGFR family members as a result of transformation, 
favoring Src phosphorylation sites on EGFR.  Phosphorylation of tyrosines 845 and 1101 
were also identified only in cells overexpressing both Src and EGFR, further suggesting 
that these phosphorylation events do not occur in untransformed cells.  Further studies are 
necessary to determine the importance of these sites.  
Initial sequencing of EGFR revealed that the predicted intracellular domain 
exhibited a high degree of conservation with the Src family of tyrosine kinases, including 
the highly conserved tyrosine residue required for Src kinase activation (tyrosine 845 of 
human EGFR) (Ullrich et al., 1984).  Based on the importance of this residue in the 
activation of other kinases, phosphorylation of EGFR by Src at tyrosine 845 in the 
activation loop was proposed to be an important regulatory event for EGFR kinase 
activity (Biscardi et al., 1999a).  In the absence of ligand, most receptor tyrosine kinases 
adopt an inactive conformation in which the activation loop of the kinase domain inhibits 
substrate binding (Huse and Kuriyan, 2002).  Ligand-induced receptor dimerization 
results in autophosphorylation of a highly conserved tyrosine residue in the activation 
loop, relieving the inhibition and creating an optimal conformation for substrate binding 
and ATP transfer (Hubbard and Till, 2000).  However, unlike all other receptor tyrosine 
kinases studied, the crystal structure of the inactive EGFR kinase domain reveals that the 
activation loop exists in an active conformation (Stamos et al., 2002).  In fact, the 
conformation of the unphosphorylated EGFR kinase domain is identical to the structure 
of the insulin growth factor receptor with its activation loop tyrosine phosphorylated.  
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These studies suggest that EGFR exists as a constitutively active kinase regulated by 
ligand binding and dimerization.  Furthermore, these data are consistent with the 
observation that tyrosine 845 phosphorylation is not required for EGFR activation (Gotoh 
et al., 1992) and the inability to detect endogenous phosphorylation at this residue in 
response to EGF. 
While the importance of EGFR phosphorylation by Src remains an open question, 
activation of Src downstream of EGFR has been documented.  Src family kinases are 
activated rapidly in response to EGF treatment and the level of Src family kinase 
activation is dependent on the expression level of EGFR, suggesting a direct activation by 
the receptor (Osherov and Levitzki, 1994).  Overexpression of Src stimulates a 2-5 fold 
increase in EGF induced DNA synthesis (Luttrell et al., 1988) and inhibition of Src 
activity by microinjection of antibodies blocks EGF stimulated DNA synthesis (Roche et 
al., 1995), demonstrating that Src is involved in mitogenic pathways downstream of 
EGFR.  However, as both Src and EGFR are tyrosine kinases, it has been difficult to 
identify specific substrates of Src phosphorylation in response EGF.  While it is generally 
accepted that Src family kinases are activated downstream of EGFR, the mechanism of 
their activation and their role in downstream signaling is not understood.  Further analysis 
of the role of Src activation in normal signaling through EGFR is required to understand 
more about the signaling pathways that may be deregulated by these kinases in cancer.  
 
Summary 
 The ErbB family of receptors and their ligands constitutes a highly complex 
signaling network that regulates diverse biological outcomes.  In particular, the ErbB 
 33 
family member EGFR has been implicated in the control of intestinal epithelial cell 
migration required for proper restitution.  Our lab, as well as others, has demonstrated 
that EGFR ligands stimulate increased intestinal cell migration in vitro and clinical trials 
have confirmed that EGF may play a role in intestinal wound healing in vivo.  The goal of 
these studies was to investigate the molecular mechanism by which EGF treatment of 
intestinal epithelial cells accelerates cell migration.  I have found that EGF stimulates a 
rapid and robust activation of the small GTPase Rac1, which requires the kinase activity 
of EGFR (Chapter III).  Further studies demonstrate that synergistic activation of PI3K 
and Src downstream of EGFR are required for EGF stimulated Rac activation (Chapter 
IV).  These data provide important insights into the mechanisms that regulate intestinal 
epithelial cell restitution with implications for potential therapeutic intervention.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Cell Culture 
The conditionally immortalized young adult mouse colon (YAMC) epithelial cell 
line isolated from the colonic epithelium of an H-2Kb-tsA58 (Immorto) mouse has been 
previously described (Whitehead et al., 1993). YAMC cells express a temperature-
sensitive mutation of SV40 large T antigen under the control of an interferon γ inducible 
promoter.  EGFR-null mouse colon epithelial (EGFR-/-MCE) cells were isolated from the 
colonic epithelium of a homozygous EGFR-null Immorto mouse (Threadgill et al., 1995) 
(Whitehead et al., 1993).  Cells were maintained on rat tail collagen (Mediatech, 
Herndon, VA) coated plates (5µg/cm2) in complete media (RPMI 1640 supplemented 
with 5% FBS, 100 U/ml penicillin and streptomycin, 5 µg/ml insulin, 5 µg/ml transferrin, 
and 5 ng/ml selenous acid (BD Biosciences, San Jose, CA)) with the fresh addition of 5 
U/ml mouse interferon gamma (IFN-γ) (Intergen, Norcross, GA) at 33°C (permissive 
conditions).  Prior to all experiments cells were washed twice in warm PBS and then 
incubated for 16-18 hours in starve media (RPMI 1640 containing 0.5% FBS and 
100U/ml penicillin and streptomycin) at 37°C (nonpermissive conditions). 
 
Antibodies, growth factors, and pharmacological inhibitors 
FITC-conjugated goat anti-mouse secondary antibody was from Jackson 
ImmunoResearch Labs (West Grove, PA). Alexa Fluor 594 Phalloidin was purchased 
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from Molecular Probes (Eugene, OR).  Mouse monoclonal Rac, Src, and rabbit 
polyclonal EGFR antibodies were from Upstate (Charlottesville, VA).  Mouse 
monoclonal EGFR antibody conjugated to phycoerythrin, EGFR (528) PE, (Santa Cruz 
Biotechnology, Santa Cruz, CA) was used for FACS analysis.  Mouse monoclonal HA-
Tag (262K), rabbit monoclonal phospho-EGFR (Tyr1173), rabbit polyclonal phospho-
Akt (Ser 473), phospho-FAK (Tyr925), ERK 1/2, Akt antibodies, and horseradish 
peroxidase (HRP)-conjugated anti-rabbit secondary antibody were from Cell Signaling 
Technology (Beverly, MA).  Anti-active ERK 1/2 polyclonal antibody was from 
Promega Corp. (Madison, WI).  Mouse monoclonal actin antibody was from Sigma-
Aldrich (St. Louis, MO).  Mouse monoclonal Cdc42, Fyn, and HRP-conjugated PY20 
antibodies, and HRP-conjugated goat anti-mouse IgG were from BD Transduction Labs 
(San Diego, CA).  Rabbit polyclonal ErbB2, PKCα, PKCδ, and PKCε antibodies were 
from Santa Cruz Biotechnology (Santa Cruz, CA).  Recombinant human EGF was a gift 
from Stanley Cohen (Vanderbilt University, Nashville, TN). Phorbol 12-myristate 13-
acetate (PMA) was purchased from Sigma (St. Louis, MO).  Rac1 inhibitor NSC23766, 
MEK 1/2 inhibitor U0126, PI3K inhibitor wortmannin, and PKC inhibitors 
Bisindolylmaleimide 1 (BIM-1) and Go6976 were from Calbiochem (San Diego, CA).  
MEK 1/2 inhibitor PD98059 and phosphoinositide 3-kinase inhibitor LY294002 were 
from Cell Signaling Technology (Beverly, MA).  Src inhibitors PP1 and PP2, and 
phospholipase C inhibitors U73122, D609, and L108, were from Biomol (Plymouth 
Meeting, PA).  Src inhibitor CGP77675 was a gift from Anna Suter (Novartis, Basel, 
Switzerland).  
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Transient transfections 
 Prior to transfection, cells were trypsinized, resuspended in complete media 
without penicillin and streptomycin, and then counted using a hemacytometer.  Cells 
were seeded in the appropriate plates as follows: 2.5 x 105 cells per 35mm plate, 5 x 105 
cells per 60mm plate, 1.5 x106 cells per 100mm plate.  The cells were grown overnight at 
33oC in the presence of IFN-γ.  The next morning, the cells were transfected with vector 
control, dominant negative Akt1, or dominant negative Akt2 by Lipofectamine 2000 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol, using exactly one 
half of the recommended concentrations of DNA and Lipofectamine 2000.  32 hours after 
transfection the cells were washed twice with warm PBS, and then starve media was 
placed on the cells.  The cells were serum starved for 16-18 hours at 37oC.  Dominant 
negative Akt constructs were a gift from Dr. Joseph Testa.  
 
Generation of stable cells 
 Tyrosine to phenylalanine (Y-F) EGFR mutations were generated from 
pcDNA3.1/Zeo(-)/EGFR (human) using QuikChange Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA).  EGFR-/-MCE cells were stably transfected with 
pcDNA3.1/Zeo(-) empty vector (Invitrogen, Carlsbad, CA), pcDNA3.1/Zeo(-)/wild type 
EGFR, pcDNA3.1/Zeo(-)/kinase dead (K721R) EGFR, or pcDNA3.1/Zeo(-)/Y-F EGFR 
mutants using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as described above for 
transient transfections.  48 hours after transfection 200µg/ml Zeocin (Invitrogen, 
Carlsbad, CA) was added to the cells to begin the stable cell selection.  The cells were 
grown in complete media with 200µg/ml Zeocin until the cells reached confluence, and 
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then the cells were expanded.  Zeocin selected pools of cells were trypsinized, suspended 
in 5% FBS/RPMI 1640, and then spun at 1500 rpm for 5 minutes.  The cells were washed 
twice in 5% FBS/PBS and then resuspended in 5% FBS/PBS at 5 x 106 cells/ml.  50µl of 
anti-EGFR 528-PE antibody was added per ml of cell suspension.  The cells were 
incubated on ice for 30 minutes, washed in PBS, and then resuspended in PBS at 5 x 106 
cells/ml.  EGFR positive cells were sorted at the Vanderbilt VAMC Flow Cytometry 
Special Resource Center using the Beckton Dickinson FACSAria.  Rounds of cell sorting 
were repeated until a pure population of cells was obtained. Stable pools of cells 
expressing EGFR were maintained in 100µg/ml Zeocin. 
 
siRNA experiments 
 Smart pools of small interfering RNA (siRNA) directed against murine Rac1, Src, 
and Fyn were purchased from Dharmacon (Lafayette, CO).  Non-targeting smart pool 
siRNA was purchased from Upstate (Charlottesville, VA).  One day prior to transfection, 
cells were plated in 35mm or 60mm plates as described above for transient transfections.  
The media was changed to Opti-MEM (Invitrogen, Carlsbad, CA) immediately before 
transfection and the cells were transfected with Lipofectamine 2000 according to the 
manufacturer’s protocol for siRNA transfection.  The cells were incubated overnight (16-
18 hours) at 33oC in Opti-MEM containing the DNA/lipid complexes.  The next morning, 
the transfection media was removed and fresh growth media was added to the cells.  For 
Rac activation assays, the cells were grown for 48 hours after transfection, serum starved 
overnight at 37oC, and lysed the following morning.  For the migration assays, the cells 
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were grown for 24 hours after transfection, the cells were serum starved overnight at 
37oC, and then wounded the following morning. 
 
Cell lysis, SDS-PAGE, and Western blot analysis 
 Serum starved cells were treated with 10ng/ml EGF at 37oC for the times 
indicated. For inhibitor studies, cells were treated with inhibitor or an equal volume of 
vehicle for 45 minutes at 37oC prior to EGF stimulation.  Immediately after treatment, 
cells were placed on ice, washed twice with cold PBS, and then lysed in Rac lysis buffer 
(50mM Tris-HCl (pH 7.5), 10mM MgCl2, 200mM NaCl, 1% (v/v) Nonidet P-40, 5% 
(v/v) glycerol) with freshly added protease and phosphatase 1 and 2 inhibitor cocktails 
(Sigma, St. Louis, MO).  The lysates were cleared by centrifugation and the protein 
concentration was determined with the DC protein assay (Bio-Rad Laboratories, 
Hercules, CA). An equal volume of 2X sample buffer was added to each cell lysate and 
the lysates were heated at 95oC for 5 minutes.  Equal protein amounts of each sample 
were separated by SDS-polyacrylamide gel electrophoresis and transferred to 
nitrocellulose membranes.  The membranes were blocked in 5% (w/v) nonfat dry milk in 
Tris buffered saline (50mM Tris, 138mM NaCl, 2.7mM KCl, pH 8.0) with 0.05% Tween 
20 (TBST) for 1 hour.  The membranes were incubated in primary antibody at the 
appropriate dilution in TBST at 4oC overnight.  The blots were washed in TBST 6 x 5 
minutes and then incubated in HRP conjugated secondary antibody diluted in TBST 
(1:5000 for anti-rabbit secondary or 1:10,000 for anti-mouse secondary antibody) for 1 
hour at room temperature.  The blots were washed in TBST 6 x 5 minutes. Bound HRP 
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was detected using Western Lightning enhanced chemiluminescence kit (Perkin-Elmer, 
Boston, MA) and the blots were exposed to film.   
 
Rac activation assays 
Rac activation was assayed as described (Benard and Bokoch, 2002).  Briefly, the 
p21-binding domain (PBD) of PAK fused to GST was expressed from pGEX-PBD, a gift 
from Josephine Adams (University College of London, London).  Recombinant GST-
PBD was purified with glutathione-Sepharose 4B beads (Pharmacia, Piscataway, NJ) and 
stored at –80oC in a solution of 10% glycerol.  Immediately after treatment, cells were 
lysed in Rac lysis buffer and the protein concentration determined, as described above.  
Equal amounts of each total lysate (500µg-1000µg) were nutated with GST-PBD beads at 
4oC for 1 hour.  The beads were collected by centrifugation, washed 3 times with washing 
buffer (25mM Tris-HCl (pH7.6), 1mM DTT, 30mM MgCl2, 40mM NaCl, 1% (v/v) 
Nonidet P-40), and twice with washing buffer without Nonidet P-40.  The beads were 
suspended in 2X SDS gel loading buffer, heated at 95oC for 5 minutes, separated on a 
15% SDS-polyacrylamide gel and blotted for Rac. 
 
Migration assays 
Cells were trypsinized, resuspended in complete media, and counted using a 
hemacytometer.  5 x 105 cells were seeded onto each 35mm plate coated with 2.5µg of 
human fibronectin (BD Bioscience, Bedford, MA) and the cells were incubated at 33oC 
overnight.  The next day the cells were washed twice with PBS, and then starve media 
was placed on the cells.  The cells were incubated in starve media at 37oC for 16-18 
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hours.  Eight circular wounds were made in each confluent plate of cells using a rotating 
silicon tip. The cells were washed twice with PBS to remove the cell debris, and then 
fresh starve media with or without 10ng/ml EGF was placed on the cells.  For migration 
assays using inhibitors, the cells were pre-treated with the inhibitor for 45 minutes prior 
to wounding, and then starve media containing fresh inhibitor was added with or without 
EGF after wounding.  The wounds were photographed at 0 and 8 hours after wounding 
and the size of each wound at 0 and hours was determined in arbitrary units using ImageJ 
software (NIH, Bethesda, MD). The data for each wound was entered into an Excel 
spreadsheet and the percent wound closure is calculated using the following equation: 
(0 hour wound size – 8 hour wound size) / 0 hour wound size x 100 = % closed 
The average wound closure rates and the standard deviation for all eight wounds were 
calculated and displayed graphically. Statistical differences in wound closure rates 
between control and EGF treated wound closure rates were determined by a paired t-test. 
 
Immunofluorescence 
 YAMC cells were trypsinized, resuspended in complete media, and counted using 
a hemacytometer.  4 x 104 cells were seeded into each well of a fibronectin coated glass 
chamber slide and the cells were incubated at permissive conditions for 24 hours.  Cells 
were serum starved at nonpermissive conditions for 16-18 hours and then circular 
wounds were made as described above.  After wounding, the cells were washed twice 
with PBS, and then treated with or without 10ng/ml EGF in fresh starve media for 5 or 10 
minutes.  Cells were fixed in 4% paraformaldehyde/PBS and permeabilized with 0.4% 
Triton-X-100 in PBS. The cells were then stained with a monoclonal Rac antibody (1:50) 
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followed by anti-mouse FITC secondary and then Alexa-594-phalloidin (3.3 nM). 
Coverslips were mounted using the Prolong Antifade Kit (Molecular Probes), and imaged 
on a Zeiss Axiovert 200 microscope. 
 
Immunoprecipitation 
 YAMC, EGFR-/- MCE vector control, wild type EGFR, and kinase dead EGFR 
stable cells were grown to confluence in 100mm plates, serum starved overnight at 37oC, 
and treated with or without 10 ng/ml EGF for 5 minutes.  The cells were lysed in Rac 
lysis buffer and the protein concentration was determined for each sample.  2µg of ErbB2 
polyclonal antibody was added to 600µg of protein for each sample.  5µl of polyclonal 
EGFR (986) rabbit sera was added to 600µg of protein for each sample.  The samples 
were nutated for 2 hours at 4oC and then 35µl of a 50:50 slurry of Protein A/G beads 
(Santa Cruz Biotechnology, Santa Cruz, CA) was added to each sample.  The samples 
were nutated for 1 hour with the beads and then the beads were washed three times with 
500µl of lysis buffer.  100µl of 2X sample was added to the beads and the samples were 
heated at 95oC for 5 minutes.  The immunoprecipitations were subjected to Western blot 
analysis for EGFR, ErbB2, or phosphotyrosine.  
 
Statistical analysis 
 Statistical significance between control and EGF treated migration rates were 
determined in Excel using a paired two-sample student’s t-test with a confidence level of 
0.05.  All data presented are representative of at least three repeat experiments. 
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CHAPTER III 
 
EPIDERMAL GROWTH FACTOR ACTIVATES THE SMALL GTPASE RAC1 TO 
STIMULATE INTESTINAL EPITHELIAL CELL MIGRATION 
 
 
 
Introduction 
 Regulated intestinal epithelial cell migration is critical for maintenance of a 
healthy gastrointestinal tract.  In response to damage, intestinal epithelial cells must 
rapidly migrate to close the wounded area and restore the integrity of the epithelium.  
Previous work from our lab and others has demonstrated that epidermal growth factor 
(EGF) treatment stimulates a migratory response from cells at the wound margin.  
However, the mechanism by which EGF elicits this effect is not understood.  Recently, a 
role for EGF in wound healing in vivo was demonstrated in a clinical trial in which 
administration of EGF-containing enemas to patients with ulcerative colitis induced 
remission in 10 out of 12 patients (Sinha et al., 2003).  In an effort to elucidate the 
molecular mechanisms involved in growth factor stimulated wound closure, I have 
investigated the role of the small GTPase Rac in EGF mediated cell migration.  Using a 
biochemical approach as well as a cell culture model of wound healing, I demonstrate 
that EGFR mediates activation of Rac in EGF stimulated intestinal epithelial cells.  These 
studies provide insight into the role of EGFR in normal intestinal epithelial cell migration 
and expand our knowledge of the pathways that may be deregulated in chronic 
gastrointestinal disorders.  
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Results 
Rac is required for EGF stimulated migration 
We have previously reported that young adult mouse colon (YAMC) epithelial 
cells exhibit increased rates of wound closure in response to EGF treatment in a wound 
closure assay that mimics ulceration in vivo (Corredor et al., 2003) (Frey et al., 2004).  In 
this assay, circular wounds are made in a confluent monolayer of serum starved cells with 
a rotating silicon tip and the cells are treated with or without 10 ng/ml EGF.  Phase 
contrast images of the wounds are taken at 0 and 8 hours after wounding (Figure 8A).  
The cell-free area of the wound is measured at these time points and the average percent 
wound closure for 8 wounds in each treatment condition is calculated and represented 
graphically (Figure 8B).  This assay mimics the process of restitution in vivo by creating 
a wound in the epithelial monolayer similar to ulceration in vivo.  In response to the 
damage, cells at the wound margin migrate over the denuded area in an attempt to reduce 
the size of the wound and restore the integrity of the epithelial layer (Figure 8A, compare 
0 hour wounds to 8 hours wounds), similar to the restitution phase in vivo.  We have 
previously demonstrated that proliferation does not contribute to the wound healing 
process observed in our assay (Corredor et al., 2003).  In fact, the rate of cell proliferation 
around the wounded area decreases in response to EGF treatment, supporting the idea 
that, similar to the phases of restitution and regeneration observed in vivo, proliferation is 
not a part of the immediate response to damage.  Therefore, we can conclude that our 
calculation of the percent wound closure is a direct measure of the rate of cell migration.  
Unlike the commonly used scrape wound assay of cell migration, which produces linear 
wounds of variable size, this assay provides a very consistent measure of cell migration  
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Figure 8. Wound closure assay. Circular wounds were made in confluent 
monolayers of serum starved YAMC cells, cells were washed twice with 
PBS, and then treated in the presence or absence of 10 ng/ml EGF.  The 
wounds were photographed at 0 and 8 hours.  Representative wounds are 
shown for control and EGF treated cells at 0 and 8 hours (A). The cell-free 
area was measured for each wound at 0 and 8 hours and the percent wound 
closure was calculated. The average wound closure for 8 control wounds 
(37.78% +/- 2.97) and 8 EGF treated wounds (56.13% +/- 1.77) from the 
experiment shown in A was calculated and graphed +/- the standard 
deviation (B). * p value < 0.001 
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because the initial size of the wounds is similar within the 8 wounds of each treatment 
condition and between the treated and untreated cells (Figure 8A).  Because EGF 
consistently stimulates a 1.5 fold increase in wound closure (56% closed with EGF vs. 
38% closed in control) (Figure 8B), this assay is amenable to the use of pharmacological 
inhibitors and other perturbations of cell signaling to study the pathways involved in EGF 
stimulated migration.   
As lamellipodia formation is the first visible sign of wound closure in both in 
vitro and in vivo models of wounding (Lacy, 1988), I hypothesized that EGF stimulates 
increased lamellipodia formation at the wound margin to promote cell migration.  While 
the requirement for activation of the small GTPase Rac in lamellipodia formation has 
been well documented (Ridley et al., 1992), the signals that activate this GTPase are still 
under investigation.  When activated, GTP-bound Rac translocates to the plasma 
membrane through its C-terminal prenylation, distinguishing it from the inactive, 
cytoplasmic Rac in the cell.  To determine if EGF stimulates Rac membrane 
translocation, Rac was immunolocalized in wounded YAMC cells treated in the presence 
or absence of 10 ng/ml EGF for 10 minutes to visualize the cellular distribution of Rac.  
The cells were co-stained with fluorescent-conjugated phalloidin, a toxin that binds to F-
actin, to visualize the actin cytoskeleton.  While both control and EGF treated cells 
contain cortical actin at the cell periphery, only YAMC cells treated with EGF exhibited 
prominent Rac staining in membrane ruffles at the wound margin (Figure 9A, see 
arrows).  To quantify this, circular wounds were made in confluent monolayers of 
YAMC cells treated with or without EGF for 10 minutes and the cells were visualized by 
phase contrast microscopy.  To determine the percentage of cells with lamellipodia at the 
EGF
%
 c
el
ls
 w
it
h 
la
m
el
li
po
di
a
0
10
20
30
40
50
*
Control
EGF
EGF
EGFcontrol
control
control
Rac
Phalloidin
Rac
Phalloidin
A.
B.
Figure 9. EGF stimulates lamellipodia formation at the wound margin. YAMC cells 
were wounded, treated with or without 10 ng/ml EGF for 10 minutes, fixed, and 
stained with Rac and Phalloidin to visualize lamellipodia formation at the wound 
margin (A). The percent of cells at the wound margin with visible lamellipodia was 
quantified with or without EGF (B). * p value < 0.001
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wound margin, the number of cells exhibiting visible lamellipodia at the wound margin 
were counted and divided by the total number of cells at the wound margin.  As shown in 
Figure 9B, EGF treatment stimulates a twofold increase in the percentage of cells 
exhibiting prominent lamellipodia at the wound margin (35.97 + 7.53 vs. 17.98 + 4.48).  
These data confirm that lamellipodia formation and Rac membrane localization are 
increased at the wound margin in response to EGF. 
Because Rac membrane translocation was increased in the presence of EGF, I 
next wanted to determine if Rac is required for EGF stimulated cell migration.  To test 
this, two different approaches were used to inhibit Rac activity.  The first approach uses a 
pharmacological Rac1 inhibitor, NSC23766, which has been shown to specifically block 
Rac-GTP loading without interfering with either Cdc42 or Rho activation (Gao et al., 
2004).  In the second approach, control non-targeting siRNA or Rac1 siRNA was 
transfected into YAMC cells to specifically reduce Rac1 protein levels.  YAMC cells pre-
treated with vehicle only or 50µM Rac1 inhibitor were wounded, treated with or without 
10 ng/ml EGF in the continued presence of vehicle or Rac1 inhibitor, and the percent 
wound closure was calculated.  In YAMC cells pre-treated with vehicle only, EGF 
stimulates a statistically significant increase in wound closure after 8 hours when 
compared to untreated cells (Figure 10A).  However, EGF stimulated wound closure is 
completely blocked in YAMC cells treated with the Rac1 inhibitor.  Consistent with these 
data, wound closure in response to EGF is completely blocked in cells transfected with 
50nM Rac1 siRNA, while cells transfected with 50nM non-targeting siRNA show the 
expected rate of increased wound closure in response to EGF (Figure 10B).  To 
determine the efficacy of the siRNA in the transfected cells, the cells were lysed after the  
B.
A.
C.
-       +       -        +EGF:
  Non
Target Rac1
Actin
Rac
0
10
20
30
40
50
*
%
 w
ou
nd
 c
lo
su
re
 a
t 8
 h
ou
rs
Vehicle Rac inhibitor
0
10
20
30
40
50
%
 w
ou
nd
 c
lo
su
re
 a
t 8
 h
ou
rs
*
Non-target Rac1 siRNA
Figure 10. Rac is required for EGF stimulated migration. Wound healing assays 
were performed with serum-starved YAMC treated with or without 10 ng/ml EGF 
either in the presence of 50µM Rac inhibitor (A) or after transfection with 50nM 
non-targeting or 50nM Rac1 siRNA (B). The cells used for the migration assay in 
B were lysed and blotted for Rac or actin as a loading control (C). * p value < 0.001
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migration assay and Rac protein levels were detected by Western blot analysis (Figure 
10C).  Transfection with Rac1 siRNA significantly reduced the amount of Rac expressed 
in YAMC cells compared to the non-targeting siRNA, while the total amount of protein 
in each lane did not change as assessed by immunoblot analysis for actin (Figure 10C).  
The specificity of the siRNA confirms that Rac1, and not other isoforms that may be 
expressed, is required for EGF stimulated wound closure and cell migration in YAMC 
cells.   
 
EGF rapidly activates Rac in YAMC cells 
To biochemically determine if EGF treatment stimulates increased lamellipodia 
formation and wound closure through activation of Rac, a GST pulldown assay was used 
to isolate GTP-bound Rac from cell lysates (Benard and Bokoch, 2002).  In this assay, a 
GST fusion protein encoding the p21 binding domain (PBD) of p21 activated kinase 
(PAK), which is activated downstream of Rac and Cdc42, is bacterially produced and 
bound to glutathione sepharose beads.  The PBD domain of PAK binds with high 
specificity to GTP-bound Rac and Cdc42, but does not recognize the GDP-bound form of 
these proteins.  Using the GST-PBD pull-down assay, confluent monolayers of YAMC 
cells treated with EGF for 0 to 60 minutes were assayed for Rac and Cdc42 activation, as 
shown in Figure 11A.  While the total cellular lysate from each time point contained 
equal levels of Rac, GTP-bound Rac was detected only in cells treated with EGF for 3 
and 5 minutes.  Active Rac was not detected at any of the later time points examined, 
suggesting that EGF rapidly and transiently activates Rac (Figure 11A).  Densitometry 
was used to determine the fold increase in Rac activation.  Compared to control cells,  
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Figure 11. EGF treatment of YAMC cells rapidly activates Rac. YAMC cells 
were treated with 10 ng/ml EGF for a long (A) or a short (B) time course for 
the indicated times. Rac and Cdc42 activation was assessed by GST-PBD pull-
down followed by Western blot analysis for Rac (A and B) or Cdc42 (A). The 
total lysates from the short time course were immunoblotted with phospho-Akt 
and phospho-ERK 1/2 antibodies to detect activation of these proteins (B). 
Densitometry was used to determine the fold increase in Rac activation 
compared to untreated cells.
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EGF treatment for 3 and 5 minutes induced a 5.4-fold and 5.1-fold increase in GTP-Rac 
levels, respectively. At 10, 15, and 30 minutes of EGF exposure GTP-Rac was similar to 
control levels (approximately 1 by densitometry), followed by a two-fold increase at 60 
minutes, which may represent a second wave of Rac activation.  Although a small 
increase in Cdc42 activation was detected at 3, 5, and 60 minutes post-EGF treatment in 
this experiment (Figure 11A), in repeated experiments performed under identical assay 
conditions, Cdc42 was not activated above basal levels in response to EGF, despite very 
consistent Rac activation at 3 and 5 minutes.  Because the activation of Cdc42 was 
inconsistent and not as robust as Rac activation, I decided to focus the remainder of my 
studies on the activation of Rac.  
To further investigate the timing of Rac activation, YAMC cells were treated with 
EGF for shorter time points between 0 and 10 minutes, as indicated, and Rac activation 
was determined by GST-PBD pull-down as above.  Densitometry was used to quantify 
the fold increase in Rac activation at each time point (Figure 11B).  Again, EGF 
stimulates rapid activation of Rac that begins with a 3-fold increase at 0.5 minutes after 
treatment, followed by a robust, 8-fold increase at 1 and 2 minutes after treatment.  Rac 
activation persists at a significant increase over control up to 6 minutes (3.8-fold), 
followed by a weaker, two-fold increase at 8 and 10 minutes (Figure 11B). EGF 
treatment of YAMC cells also rapidly activates Akt and ERK 1/2 (Figure 11B), as 
detected by phospho-specific antibodies that recognize only the active, phosphorylated 
forms of these proteins.  Interestingly, maximal Rac activation is detected 1 minute after 
EGF treatment, prior to ERK 1/2 and concomitant with minimal Akt activation, further 
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supporting that the signaling pathways that activate Rac are independent or upstream of 
the cell proliferative (ERK 1/2) and cell survival (Akt) pathways.   
In our wound healing assay, lamellipodia formation at the wound margin is 
stimulated following EGF treatment, but lamellipodia are also visible in untreated cells, 
suggesting that Rac is activated in these cells as well (Figure 9B).  Consistent with this, 
basal cell migration is observed in untreated cells in response to wounding, albeit at a 
much slower rate than EGF treated cells (Figure 8B).  Because the biochemical 
experiments assessing Rac activation were performed in confluent monolayers of cells 
that were not actively migrating, it is plausible that the increase in GTP-Rac levels in 
response to EGF may not be maximal under these conditions.  To examine this 
possibility, confluent plates of serum starved YAMC cells were wounded using a gel 
comb to make multiple scratch wounds across the plate.  After wounding, cells were 
incubated either in starve media only for 3 or 60 minutes or in starve media containing 10 
ng/ml EGF for 3, 10, 15, 30, or 60 minutes.  The cells were lysed, Rac activation was 
determined by GST-PBD pull-down, and the fold increase in GTP-Rac was quantified by 
densitometry.  As shown in Figure 12, wounding alone stimulated a 6-fold increase in 
GTP-Rac after 3 minutes, representing a fold increase in Rac activation similar to EGF 
treatment alone in confluent cells (Figure 11A).  The combination of wounding and EGF 
treatment increased GTP-Rac levels 11-fold, demonstrating that GTP-Rac levels 
activated by wounding alone are enhanced by EGF treatment.  Interestingly, Rac 
activation was sustained 5- to 6-fold in wounded cells treated with EGF over control cells 
at all of the longer time points examined (Figure 12).  This increase in Rac activation at 
later time points was not observed in previous experiments in which confluent YAMC  
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Figure 12. Wounding activates Rac and sustains EGF stimulated Rac activation.
Multiple scrape wounds were made in confluent, serum-starved YAMC cells and 
the cells were incubated for 3 or 60 minutes after wounding only or treated with 
10 ng/ml EGF immediately after wounding for 3, 10, 15, 30, or 60 minutes. The
cells were lysed and Rac activation was determined by GST-PBD pull-down. 
Western blot analysis of the total lysate was used to detect activation of ERK 1/2,
Akt, or EGFR using phospho-specific antibodies. Immunoblot analysis of total 
Rac and Akt confirmed equal loading of the gels. Densitometry was performed
to determine the fold increase in Rac activation compared to untreated cells. 
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cells were treated with EGF only (see Figure 11A).  Rac activation was slightly elevated 
(two-fold) after 60 minutes of wounding only (Figure 12), similar to the elevation 
observed following EGF treatment of confluent monolayers for 60 minutes (Figure 11A).  
These data demonstrate that Rac is activated by the mechanical stimulus of wounding and 
that this activation is both increased and potentiated by the presence of EGF.   
To determine if wounding activated any proteins known to be downstream of 
EGF, Western blot analysis was used to assess activation of ERK 1/2, Akt, and EGFR 
with phospho-specific antibodies.  Interestingly, these proteins were only activated by 
EGF treatment, including EGFR as determined by antibodies that recognize two of its 
major autophosphorylation sites, pY1068 and pY1173.  These results demonstrate that 
basal Rac activation in response to wounding may not require activation of EGFR, and 
further suggest that enhanced Rac activation in response to EGF likely occurs through a 
different pathway.  
 
EGFR kinase activity is required for EGF stimulated Rac activation 
Because EGF binds preferentially to EGFR among the ErbB family receptors 
(Jones et al., 1999), EGFR is most likely the receptor required for EGF stimulated Rac 
activation. To test the contribution of the other ErbB family members to EGF stimulated 
Rac activation, I utilized EGFR-/- mouse colon epithelial (MCE) cells derived from an 
immortomouse homozygous for targeted disruption of EGFR (Threadgill et al., 1995). 
These cells express endogenous levels of ErbB2, ErbB3, and ErbB4, but lack any 
detectable EGFR expression.  EGFR-/- MCE or YAMC cells were treated with 10 ng/ml 
EGF for the indicated times (Figure 13A), and Rac activation was assessed by GST-PBD  
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Figure 13. EGFR, but not ErbB2 is required for EGF stimulated Rac activation.
Serum starved EGFR-/- MCE cells were treated with 10 ng/ml EGF from 0 to 60 
minutes as indicated. Rac activation was assessed by GST-PBD pulldown assay
followed by Western blot analysis for Rac (A). YAMC cells were used as a positive 
control for Rac activation (A). Serum starved YAMC cells were pre-treated with 
either DMSO, 10µM AG879 (ErbB2 inhibitor), or 150nM AG1478 (EGFR 
inhibitor), stimulated with 10 ng/ml EGF for 3 minutes, and Rac activation was 
assessed as in A (B).
55
 56 
pull-down.  Whereas EGF exposure activated Rac in YAMC cells after 3 minutes as 
expected, EGFR-/- MCE cells failed to activate Rac at any of the time points tested 
(Figure 13A).  These data confirm that EGF stimulates Rac activation only in the 
presence of EGFR.   
Exposure of cells to EGF preferentially activates EGFR homodimerization, but 
EGF can also stimulate EGFR heterodimerization with ErbB2, ErbB3, or ErbB4.  ErbB2 
is the most likely candidate for EGFR heterodimerization because it is the preferred 
heterodimerization partner for all of the ErbB family members (Graus-Porta et al., 1997).  
To determine if ErbB2 is required for EGF stimulated Rac activation, pharmacological 
inhibitors of ErbB2 (AG879) and EGFR (AG1478) were used to block activation of each 
of these receptors individually.  YAMC cells were pre-treated with vehicle only (DMSO), 
10µM AG879, or 150nM AG1478 prior to treatment with 10 ng/ml EGF for 3 minutes 
and Rac activation was assessed as described above.  As shown in Figure 13B, pre-
treatment with an EGFR specific inhibitor completely blocks EGF stimulated Rac 
activation.  Pre-treatment of these cells with vehicle only (DMSO) or an ErbB2 inhibitor 
fails to attenuate activation of Rac, suggesting that ErbB2-EGFR heterodimers are not the 
active dimers upstream of Rac activation (Figure 13B). 
 EGF binding to EGFR not only induces receptor dimerization, but also is 
associated with increased kinase activity and trans-autophosphorylation of tyrosine 
residues in the C-terminus of EGFR.  Inhibition of Rac activation by AG1478 suggests 
that activation of EGFR kinase activity is required for Rac activation (Figure 13B).  To 
test this more thoroughly, EGFR-/- MCE cells were transfected with either empty vector, 
wild type human EGFR, or kinase dead (K721R) human EGFR.  Stable pools of cells 
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expressing these transgenes were generated by FACS analysis using an antibody that 
recognizes the extracellular domain of EGFR, thus allowing the requirement for EGFR 
kinase activity in downstream signaling pathways to be assessed.  A time course of EGF 
treatment was performed to determine if Rac is activated in the wild type EGFR add-back 
cells.  EGFR-/-MCE wild type EGFR cells were treated with 10 ng/ml EGF for 0, 1, 3, 5, 
7, or 9 minutes and Rac activation was assessed.  As shown in Figure 14A, GTP-Rac is 
detected in the wild type add-back cells at 1 and 3 minutes after EGF treatment.  YAMC 
cells were used as a positive control.  Interestingly, Rac activation in the wild type add-
back cells is very transient, with robust GTP-Rac detected only at 1 minute, compared to 
the YAMC cells in which Rac activation is sustained up to 6 minutes post EGF treatment 
(Figure 11B).  The differences in Rac activation between YAMC and EGFR-/- MCE wild 
type cells are not the result of a generalized defect in signaling as activation of ERK 1/2 
is identical between these cell lines (compare Figure 14A with Figure 11B), but instead 
may reflect alterations in specific signaling pathways that result from the introduction of 
exogenous EGFR in these cells.  A similar time course was performed in the kinase dead 
EGFR stable cells to assess the effect of this mutation (K721R) on Rac activation.  In 
contrast to the wild type add-back cells, kinase dead stable cells do not activate Rac or 
ERK 1/2 at any of the time points tested, demonstrating that the kinase activity of EGFR 
is required for activation of both of these downstream targets in response to EGF (Figure 
14B).  Western blot analysis confirmed EGFR expression in the stable cells, but the 
relative levels of expression can not be compared to the YAMC cells because the 
antibody used for immunoblot analysis may not recognize mouse (YAMC) and human 
(stable cells) EGFR with the same affinity (Figure 14 A and B). 
A.
B.
Figure 14. EGFR kinase activity is required for Rac activation. EGFR-/- mouse
colon epithelial (MCE) cells stably transfected with either wild type (w.t.) EGFR
(A) or kinase dead (k.d.) EGFR (B) were treated with 10 ng/ml EGF for the 
times indicated. Rac activation was assessed by GST-PBD pulldown.  The total 
lysates were blotted for phospho-ERK 1/2 and total EGFR to confirm expression 
in the stable cells. 
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To directly compare EGFR levels and Rac activation in the wild type and kinase 
dead add-back cells, YAMC, EGFR-/- MCE vector control, wild type EGFR, and kinase 
dead EGFR stable cells were treated with 10 ng/ml EGF for 3 minutes and Rac activation 
was analyzed by GST-PBD pull-down.  Although Rac activation is not maximal at 3 
minutes in the wild type EGFR stable cells, this time point was selected because ERK 1/2 
is activated at this time, allowing comparison of downstream signaling pathways between 
the different cell lines.  As shown in Figure 15A, GTP-Rac is detected in both YAMC 
and wild type EGFR cells, but not in vector control or kinase dead EGFR cells treated 
with EGF.  Western blot analysis for EGFR confirms that the receptor is expressed in 
both of the stable pools.  Interestingly, the kinase dead stable pools express more EGFR 
than the wild type stable pools; however, Rac, Akt, and ERK 1/2 are not activated in 
these cells, confirming that activation of each of these pathways requires EGFR kinase 
activity.  In agreement with this, expression of wild type EGFR restores EGF stimulated 
Akt and ERK 1/2 activation in the null cells to levels comparable to those observed in 
YAMC cells.     
 The ability of wild type EGFR stable cells to activate Rac in response to EGF 
treatment (Figure 15A) suggests that EGF stimulated migration should similarly be 
restored in these cells.  To confirm that loss of EGFR kinase activity and downstream 
signaling in response to EGF translates to reduced cell migration, YAMC, EGFR-/- MCE 
vector control, wild type, or kinase dead stable cells were subjected to our wound healing 
assay in the presence or absence of 10 ng/ml EGF.  As predicted, EGFR-/- MCE vector 
control cells did not exhibit increased migration in the presence of EGF (Figure 15B), 
consistent with the lack of signaling in response to EGF in these cells (Figure 15A).   
A.
B.
GTP-Rac
Total Rac
pAKT
EGFR
pERK 1/2
3  ʼEGF:
Actin
-      +     -      +     -     +     -      +
YAMC  vector
wild
type
kinase
dead
EGFR-/- MCE stable pools
Figure 15. Wild type, but not kinase dead, EGFR stimulates Rac activation and cell 
migration in response to EGF. YAMC or EGFR-/- stable cellls expressing empty vector, 
wild type, or kinase dead EGFR were treated with or without 10 ng/ml EGF and Rac 
activation was assessed by GST-PBD pulldown. The total cell lysates were blotted for 
EGFR, phospho-Akt and ERK 1/2, or actin as a loading control (A). A wound healing 
assay was performed with the cells used in A in the presence or absence of 10 ng/ml
EGF. * p value < 0.001
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EGFR-/- MCE cells transfected with wild type EGFR respond to EGF treatment with an 
increased wound closure rate similar to YAMC cells (Figure 15B).  EGFR-/- MCE kinase 
dead stable cells showed no increase in cell migration at 8 hours, similar to the vector 
control cells (Figure 15B).  These data are consistent with the signaling data (Figure 15A) 
and confirm that wild type, but not kinase dead, EGFR can restore EGF stimulated Rac 
activation and cell migration in EGFR-/- MCE cells.  
One interesting caveat to these experiments appeared in a total phosphotyrosine 
blot of the EGFR-/- stable cells.  As expected, EGFR-/- vector control cells fail to respond 
to EGF treatment, while wild type add-back cells show a profile of phosphorylated 
proteins in response to EGF similar to the YAMC cells (data not shown).  Unexpectedly, 
a high molecular weight band at approximately 180 kDa appeared in the EGF treated 
kinase dead cells that was not present in the untreated cells.  To determine if 
phosphorylation of this band correlated with the levels of kinase dead EGFR expression, 
EGFR-/- stable cells were generated expressing either low or high levels of kinase dead 
EGFR.  YAMC, EGFR-/- vector control, kinase dead low, or kinase dead high expressing 
stable cells were treated with EGF for 3 minutes and EGFR and phosphotyrosine levels 
were determined by Western blot analysis.  Intriguingly, increased phosphorylation of 
this high molecular weight band directly correlated with increased expression of kinase 
dead EGFR, suggesting that kinase dead EGFR is required for this phosphorylation 
(Figure 16A).  Because kinase dead EGFR contains a functional ligand binding domain, 
this band may be the result of heterodimerization of kinase dead EGFR with ErbB2 in 
response to ligand.  Kinase dead EGFR-ErbB2 heterodimerization can result in trans-
phosphorylation of EGFR by ErbB2, autophosphorylation of ErbB2, or phosphorylation  
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Figure 16. ErbB2 and EGFR are phosphorylated in EGFR-/- MCE kinase dead stable
cells. YAMC, vector, or kinase dead EGFR-/- MCE stable cells expressing low and 
high levels of receptor were treated with 10 ng/ml EGF for 3 minutes, lysed and 
immunoblot analysis for EGFR and phosphotyrosine was performed (A). ErbB2 and 
EGFR were immunoprecipitated from YAMC, vector, wild type, kinase dead EGFR-/- 
MCE stable cells, and immunoblotted for ErbB2, EGFR, or phosphotyrosine (B).
EGFR-/- MCE stable pools
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of both receptors by ErbB2, but not phosphorylation of any direct substrates of EGFR.  
Consistent with this idea, the only phosphorylated proteins observed in the total 
phosphotyrosine blot of kinase dead cells treated with EGF are similar in size to EGFR 
and ErbB2, and no lower molecular weight proteins representative of EGFR substrates 
are increased even in cells expressing high levels of kinase dead EGFR (Figure 16A).  To 
determine if kinase dead EGFR and/or ErbB2 are phosphorylated in the kinase dead cells, 
EGFR and ErbB2 were immunoprecipitated from YAMC, EGFR-/- vector control, wild 
type EGFR, or kinase dead EGFR cells treated with or without 10 ng/ml EGF for 3 
minutes and phosphorylation of the receptors was detected by immunoblot analysis for 
total phosphotyrosine.  In YAMC and EGFR-/- wild type EGFR cells, EGFR was heavily 
tyrosine phosphorylated in response to EGF (Figure 16B).  While equal amounts of 
ErbB2 were immunoprecipitated from all of the cell lines, the levels of ErbB2 
phosphorylation are increased in wild type cells compared to YAMC cells, suggesting 
that more EGFR-ErbB2 heterodimers are formed in these cells in response to EGF. 
However, the robust phosphorylation of EGFR in both YAMC and wild type add-back 
cells suggests that EGFR homodimers are predominant in both cell lines in response to 
EGF.  Interestingly, in EGFR-/- kinase dead stable cells, both EGFR and ErbB2 are 
phosphorylated in response to EGF, although phosphorylation of both of these receptors 
is significantly reduced compared to wild type add-back cells (Figure 16B).  Consistent 
with the phosphotyrosine blot in Figure 16A, EGFR and ErbB2 are not phosphorylated in 
vector control cells.  These data suggest that kinase inactive EGFR heterodimerizes with 
ErbB2 in the EGFR-/- kinase dead stable cells; however, the biological consequences of 
these dimers, if any, is unclear.  Together, these data demonstrate that increased Rac  
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activation is induced by signaling pathways downstream of functional EGFR 
homodimers and that enhanced activation of Rac contributes to increased cell motility in 
response to EGF. 
 
Discussion 
Previous work from our lab as well as others has demonstrated that EGF 
stimulates increased motility in a wound healing model of cell migration (Frey et al., 
2004) (Wilson and Gibson, 1999).  My studies have extended these previous observations 
to characterize the role of the small GTPase Rac1 in EGF stimulated migration.  While 
many different signaling pathways contribute to the complex process of cell migration, I 
have demonstrated that activation of Rac1 is necessary for EGF stimulated migration in 
our wound closure assay.  Targeted reduction of Rac1 protein expression inhibits YAMC 
cell migration in response to EGF.  More specifically, the GTPase activity of Rac is 
required, as treatment of cells with a pharmacological inhibitor that blocks Rac GTP-
binding also inhibits EGF stimulated migration.  Biochemical experiments used to 
determine GTP-Rac levels confirm that Rac is rapidly and robustly activated in YAMC 
cells either in response to EGFR ligand binding or through wounding of the cell 
monolayer.  In fact, Rac activation precedes the activation of other well-known signaling 
pathways downstream of EGFR, underscoring its importance in the immediate phase of 
the restitution process.  These data provide important insight into the mechanism by 
which growth factors stimulate actin-based motility.      
Whereas EGF stimulates increased migration in YAMC cells in our wound 
closure assay, lamellipodial extension and cell movement into the denuded area still 
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occur in the absence of EGF, albeit with reduced kinetics (Figure 8A and 8B, Figure 9B).  
As these processes are regulated by the small GTPase Rac, it is likely that Rac is 
activated in response to wounding and therefore, an effector of both growth factor 
stimulated and basal migration (Nobes and Hall, 1999).  Consistent with this idea, scrape 
wounding of confluent YAMC cells in the absence of growth factor induces Rac 
activation (Figure 12) to a similar extent to which EGF activates Rac in confluent 
monolayers.  I have demonstrated that EGF treatment in combination with wounding of 
the monolayer both increases and potentiates Rac activation.  This suggests that EGF 
enhances the basal migratory response, potentially through sustained activation of 
signaling pathways that contribute to Rac activation.  However, it is still unclear whether 
the upstream signals that contribute to Rac activation in response to wounding and in 
response to EGF are similar.  One possibility is that loss of cell:cell contacts and the 
ensuing actin cytoskeletal rearrangement in response to the mechanical stimulus of 
wounding activates a Rac-specific GEF and that EGF treatment activates this GEF as 
well.  Alternatively, EGF treatment might activate a completely different GEF from that 
activated by wounding, and the combination of this activation leads to increased GTP-
Rac levels.  Future experiments will be directed at understanding the signals that 
contribute to basal migration in response to wounding to determine if they are distinct 
from EGF stimulated signaling pathways.   
Interestingly, one study has demonstrated that inhibitors of EGFR significantly 
block basal migration of colon cancer cells in a wound healing assay similar to our own 
(Wilson and Gibson, 1999).  Additionally, blocking antibodies to TGFα, but not to EGF, 
also inhibit basal migration.  This suggests that wounding stimulates the release of TGFα, 
 66 
which in turn activates EGFR to stimulate migration in intestinal cells.  However, the 
signaling pathways activated by EGFR that may contribute to basal migration have not 
been identified.  Inconsistent with this idea, phospho-specific antibodies to two different 
EGFR phosphorylation sites failed to detect EGFR activation in response to wounding 
(Figure 12).  It is possible that wounding may stimulate EGFR phosphorylation on sites 
different from those examined in my studies, or that EGFR activation may occur very 
transiently in response to wounding.  A more detailed time course is necessary to 
determine if wounding alone activates EGFR.  Furthermore, it is possible that EGFR is 
only activated in cells at the wound margin and this activation may not be detectable by 
our phospho-specific antibodies.  Together, these data suggest a model in which wounded 
cells activate Rac at the wound margin and begin to migrate slowly as they sense the 
denuded area.  I propose that in cells exposed to EGF, Rac activation occurs more rapidly 
as cells at the wound margin both sense the denuded area and bind to ligand, coordinately 
and potently activating the migratory pathways downstream of EGFR to enhance cell 
migration.  It will be interesting to determine in future studies whether the different 
signaling cues of growth factors and the mechanical stimulus of wounding employ 
similar downstream effector molecules to elicit cell migration.   
In confluent monolayers of cells, EGF stimulates a rapid and transient activation 
of Rac in the absence of wounding (Figure 11).  Activation of Rac begins within 30 
seconds of EGF exposure and reaches maximal activation within 1 minute, prior to 
maximal activation of Akt or ERK 1/2 (Figure 11B).  The rapid time course of activation 
in relation to other well-characterized EGFR downstream pathways suggests that signals 
upstream of Rac must be activated almost immediately upon EGF exposure.  
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Characterization of the signaling pathways activated within the first 30 seconds of EGF 
treatment will provide candidate signaling molecules upstream of Rac. Interestingly, 
studies have demonstrated that filopodial extensions direct the formation of lamellipodia, 
suggesting that Cdc42 activation is upstream of Rac activation (Nobes and Hall, 1995).  
Although I was unable to consistently detect Cdc42 activation, these experiments are not 
conclusive enough to assess the requirement for Cdc42 in Rac activation.  Cdc42 induces 
the formation of transient and labile filopodial extensions that may only require a low 
level of Cdc42 activity that may be below the threshold of detection by GST-PBD 
pulldown assays.  Alternatively, Cdc42 activation might reach maximal levels prior to the 
time points examined in these experiments.  Further studies are necessary to determine 
whether Cdc42 is activated by EGF and whether if functions upstream of Rac activation 
in intestinal epithelial cells.    
 Unlike activation of Akt and ERK 1/2, which are sustained for up to 10 minutes 
following EGF treatment, Rac activation occurs more transiently, returning to basal 
levels at 8 minutes after treatment.  This transient activation of Rac is characteristic of the 
small GTPases, which rapidly hydrolyze GTP to GDP after activation through their 
intrinsic GTPase activity.  Interestingly, increased Rac activation was observed 60 
minutes after EGF treatment, although this activation was reduced compared to activation 
at 3 and 5 minutes (Figure 11A).  As cells move forward, they must continually cycle 
through the processes of lamellipodial extension, cell body contraction, and rear release, 
requiring cyclical activation of the Rho GTPases as well (reviewed in (Raftopoulou and 
Hall, 2004)).  This increase in GTP-Rac levels at 60 minutes may represent a second 
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cycle of Rac activation; however, a more detailed time course of EGF treatment from 30 
to 60 minutes is necessary to confirm this observation.   
Rac activation in response to EGF requires the kinase activity of EGFR, but not 
ErbB2 kinase activity, suggesting that signaling pathways downstream of EGFR 
homodimers induce GTP-Rac.  EGFR null cells do not activate Rac or migrate in 
response to EGF, suggesting that EGF does not signal through other receptors in these 
cells.  These cell provide a perfect model system for reconstitution of EGFR signaling by 
expressing wild type and kinase dead EGFR in the absence of endogenous receptor.  
Lysine 721 of EGFR is required for ATP binding and mutation of this residue abrogates 
all tyrosine kinase activity and cellular responses to EGF, but does not alter ligand 
binding affinity (Chen et al., 1987) (Honegger et al., 1987).  Surprisingly, expression of 
kinase dead EGFR in the EGFR-/- cells results in phosphorylation of EGFR and ErbB2 in 
response to EGF treatment, suggesting that EGFR ligand binding activates ErbB2.  In the 
low and high EGFR-/- kinase dead expressing cells, phosphorylation of both of these 
receptors directly correlates with increased levels of kinase dead EGFR, suggesting that 
increased availability of the active ligand binding domain of EGFR drives activation of 
ErbB2.  It has yet to be determined if these heterodimers are functional, as no signaling 
proteins have been found to be activated in these cells.  In contrast, co-expression of 
K721M kinase dead EGFR and ErbB2 in 32D myeloid cells, which do not express any 
endogenous ErbB receptors, resulted in phosphorylation and activation of ERK 1/2 and 
Akt in response to EGF treatment for 5 minutes (Deb et al., 2001).  This demonstrates 
that signaling pathways can potentially be activated by kinase dead EGFR-ErbB2 
heterodimers.  These contradictory data may be explained by differences in ErbB2 
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expression levels, as our cells express endogenous levels of ErbB2.  However, it is also 
possible that our kinase dead cells activate different signaling pathways in response to 
tyrosine phosphorylation.  One possibility is that a unique subset of EGFR tyrosine 
residues are phosphorylated by ErbB2, limiting the recruitment of adaptor proteins to the 
receptor.  These cells provide an excellent model to study the contributions of ErbB2 to 
EGFR phosphorylation.  Determining the identity of the phosphorylated tyrosine residues 
on ErbB2 and kinase dead EGFR is necessary to learn more about how these receptors 
may signal.  The inability of the kinase dead cells to migrate in response to EGF 
demonstrates that if signaling pathways are activated in these cells, they are not sufficient 
to induce cell motility.  Furthermore, these studies need to be extended to determine if 
EGF activates ErbB3 and ErbB4 in these cells.  In summary these studies provide a 
foundation for further investigation into the signaling pathways involved in both basal 
and EGF stimulated migration that contribute to Rac activation.    
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CHAPTER IV 
 
RAC ACTIVATION REQUIRES PHOSPHOINOSITIDE 3-KINASE AND SRC 
FAMILY KINASE ACTIVITY 
 
 
 
Introduction 
 In response to ligand binding, EGFR dimerizes, trans-autophosphorylates on 
tyrosine residues located in its C-terminal tail, and recruits a number of adaptor proteins 
with SH2 and PTB binding domains to activate downstream signaling events (see Figure 
7).  In addition to autophosphorylation of the receptor, a number of other proteins are 
tyrosine phosphorylated in response to EGF, either directly by EGFR or by kinases 
activated downstream of EGFR, such as the Src family kinases.  Data presented in the 
previous chapter demonstrated that the small GTPase Rac1 is activated in response to 
EGF treatment and that this activation requires the kinase activity of EGFR.  However, 
the pathways downstream of EGFR required for Rac activation have not been 
investigated. The purpose of these experiments was to investigate the molecular 
mechanism by which ligand engaged EGFR stimulates Rac-GTP levels. Because EGFR 
activation leads to many different cellular processes, I hypothesized that a subset of 
signaling pathways downstream of EGFR would be required for Rac activation while 
others would be dispensable for its activation. To identify those specific pathways, a 
panel of small molecule inhibitors and dominant negative constructs were used to disrupt 
signaling through EGFR.  Included in these studies were pathways previously shown to 
be required for EGF stimulated migration, but whose role in Rac activation was 
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unknown.  Collectively, I find that stimulation of Rac-GTP levels is complex and 
requires the synergistic effects of two different signaling pathways. 
 
Results 
PLC and PKCs are not required for Rac activation 
 Previous work has demonstrated that phospholipase C (PLC) activity is required 
for EGF stimulated cell migration (Chen et al., 1994b) (Polk, 1998), suggesting that 
activation of PLC by EGF may be involved in Rac activation.  To test this, PLC activity 
was inhibited in YAMC cells with three different pharmacological inhibitors.  YAMC 
cells were pre-treated with either vehicle only (DMSO) or the PLC inhibitors 2µM 
U73122, 100µM D609, and 10µM L108 prior to stimulation with 10 ng/ml EGF for 3 
minutes and Rac activation was determined by GST-PBD pull-down.  As shown in 
Figure 17A, Rac was activated in the presence of each of the PLC inhibitors similar to the 
vehicle treated cells.  In each case, the PLC inhibitors had no effect on activation of ERK 
1/2, suggesting that they did not non-specifically inhibit EGFR signaling (Figure 17A).  
In this experiment the efficacy of the PLC inhibitors was not confirmed; however, we 
have previously demonstrated that EGF stimulated IP3 formation is inhibited by U73122, 
D609, and L108 at the concentrations used in this experiment (Polk, 1998).  Therefore, 
these data demonstrate that Rac activation does not require PLC activity.   
 When activated by EGF, PLC generates diacylglycerol (DAG) and IP3, which in 
turn activate protein kinase C (PKC) family members.  As we have previously shown that 
activation of PKCs downstream of PLC is also required for EGF stimulated migration 
(Polk, 1998), the PLC inhibitor data suggest that PKCs are not involved in Rac  
Figure 17. PLCγ and PKC activation are not required for EGF stimulated Rac
activation. Serum-starved YAMC cells were pre-treated with either DMSO or 
PLCγ inhibitors 2µM U73122, 100µM D609, or 10µM L108 and then treated
with 10ng/ml EGF for 3 minutes. Rac activation was assessed by GST-PBD
pulldown and Western blot analysis for Rac. The total lysate was probed for total 
Rac and phospho-ERK 1/2 (A). Rac activation was assessed as in A in YAMC 
cells pre-treated with DMSO or PKC inhibitors 5µM BIM-1 or 1µM Go6976 (B).
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activation.  To test the requirement for PKCs, YAMC cells were pre-treated with either 
vehicle or pharmacological PKC inhibitors, 5µM Bisindolylmaleimide 1 (BIM-1) and 
1µM Go6976, prior to treatment with 10ng/ml EGF and Rac activation was assessed. 
Pharmacological inhibition of PKCs did not affect GTP-Rac levels in response to EGF, 
demonstrating that these kinases are not involved in Rac activation (Figure 17B).   
The PKC family consists of 11 different isoforms, some of which are not 
effectively blocked by these inhibitors.  With this in mind, I utilized a more general 
approach to inhibit PKC activity.  Phorbol 12-myristate 13-acetate (PMA) is a potent 
analog of DAG that directly binds to and activates PKCs, bypassing the requirement for 
PLC activity.  In response to continuous activation, PKC activity is inhibited through its 
subsequent downregulation.  Long-term treatment with PMA results in a potent reduction 
in PKC levels within the cell as a result of downregulation, while short-term PMA 
treatment potently activates PKCs.  I have taken advantage of both of these mechanisms 
of PKC regulation to determine the requirement for PKCs in Rac activation.  YAMC 
cells were treated with vehicle or 1µM PMA for 24 hours prior to stimulation with 10 
ng/ml EGF for 3 minutes.  The cells were lysed and Rac activation was determined using 
the GST-PBD pull-down assay.  Western blot analysis for PKCα and PKCε, two 
predominant PKC isoforms found in YAMC cells, demonstrates a significant reduction in 
the expression levels of both of these proteins after 24 hour treatment with PMA (Figure 
18A).  PKCδ, a third isoform expressed in YAMC cells, is also downregulated in 
response to 24 hour PMA treatment (data not shown).  Despite a significant reduction in 
the protein expression levels of all PKC isoforms known to be expressed in these cells, 
Rac was still activated in response to EGF (Figure 18A).  Alternatively, YAMC cells  
A.
Total Rac
Rac-GTP
PKC α
PKC ε
-       +       -       +
Vehicle
1µM PMA
24 hours
3  ʼEGF:
B.
Total Rac
Rac-GTP
pERK 1/2
 0       1.5  ʼ     3  ʼ      5  ʼ     7  ʼ     10  ʼ     -100nM PMA:
EGF: -       -       -       -      -       -        3ʼ
Figure 18. Rac activation does not require PKCs. YAMC cells pre-treated with 
1µM PMA for 24 hours to downregulate PKCs were stimulated with 10 ng/ml
EGF for 3 minutes and Rac activation was assessed by GST-PBD pulldown. 
Reduction of PKCα and ε was confirmed by Western blot analysis (A). YAMC 
cells were treated with 100nM PMA for the times indicated to stimulate PKC 
activation and Rac activation was assessed as in A. 10 ng/ml EGF treatment for 
3 minutes was used as a positive control and phospho-ERK 1/2 Western blot 
analysis confirmed that the cells responded to the PMA treatment (B).
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were treated with 100nM PMA for either 1, 1.5, 3, 5, 7, or 10 minutes to stimulate PKCs.  
While ERK 1/2 was activated in response to PMA treatment, PKC activation failed to 
stimulate an increase in GTP-Rac levels compared to 3-minute EGF treatment as a 
positive control at any of the time points tested (Figure 18B).  
 
PI3K, but not Akt or MEK 1/2 activity, is required for Rac activation 
As demonstrated in Figure 11B, both Akt and ERK 1/2, downstream targets of 
phosphoinositide 3-kinase (PI3K) and MAPK, respectively, are rapidly and robustly 
activated in YAMC cells in response to EGF as detected by phospho-specific antibodies.  
While EGFR does not possess any direct binding sites for the p85 subunit of PI3K within 
its C-terminus, PI3K activity is required for Akt activation.  Therefore, it is assumed that 
PI3K is activated in response to EGF in YAMC cells, presumably through recruitment of 
the adaptor protein Gab1 to EGFR (Mattoon et al., 2004).  In addition to Akt, many other 
signaling proteins that contain pleckstrin homology (PH) or FYVE domains are recruited 
to the membrane in response to PI3K activation (Rameh and Cantley, 1999).  Tandem PH 
and Dbl homology (DH) domains characterize guanine nucleotide exchange factors 
(GEFs) for the Rho family of GTPases (Rossman et al., 2005).  While the DH domain is 
required to catalyze the exchange of GDP for GTP, the PH domain is thought to localize 
the GEF to the membrane.  Therefore, I hypothesized that EGF stimulated PI3K activity 
would be required for Rac activation through recruitment of a Rac-specific GEF.  
Recruitment of either Grb2 or Shc to EGFR phosphotyrosines initiates the MAPK 
cascade through activation of Sos, followed by Ras, Raf, MEK 1/2, and ERK 1/2 
activation to stimulate cell proliferation.  Because EGF stimulated proliferative signals 
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are likely to be independent from migratory signals, I hypothesized that activation of the 
MAPK cascade would not be required for Rac activation.  To test these hypotheses, 
pharmacological inhibitors of PI3K and MEK 1/2 were employed to inhibit each of these 
signaling pathways.  First, YAMC cells were pre-treated with vehicle only (DMSO), the 
PI3K inhibitors 50µM LY294002 or 200nM Wortmannin, or the MEK 1/2 inhibitor 
10µM U0126.  The cells were stimulated with 10 ng/ml EGF and Rac activation was 
assessed by GST-PBD pull-down.  Treatment of YAMC cells with PI3K inhibitors, 
LY294002 or Wortmannin, inhibited EGF stimulated Rac activation, whereas MEK 1/2 
inhibition had no effect (Figure 19A).  The efficacy of these inhibitors was confirmed by 
immunoblot analysis of the total cell lysate for phospho-Akt and phospho-ERK 1/2.  Both 
of the PI3K inhibitors blocked Akt activation, while the MEK 1/2 inhibitor blocked 
activation of ERK 1/2, as expected (Figure 19A).  Because Akt is activated in response to 
PI3K, it was plausible that Akt activation and not PI3K activity is required for Rac 
activation.  To test this, YAMC cells were transiently transfected with dominant negative 
Akt1 or Akt2, treated with or without 10ng/ml EGF for 3 minutes, and then subjected to 
Rac activation assays.  Western blot analysis for phospho-Akt confirmed that expression 
of dominant negative Akt1 and Akt2 attenuated EGF stimulated Akt activation (Figure 
19B).  Despite the decrease in Akt activity, GTP-Rac levels were increased similarly in 
response to EGF in vector and dominant negative Akt transfected cells. Western blot 
analysis for HA confirmed that dominant negative Akt was expressed at equal levels in 
the transfected cells (Figure 19B).  These data demonstrate that PI3K activity is required 
for EGF stimulated Rac activation independent of Akt activity.  Because pharmacological 
inhibitors can exhibit non-specific effects, a different MEK 1/2 inhibitor, PD98059, was  
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Figure 19. PI3K activity is required for Rac activation independent of Akt. YAMC 
cells were pre-treated with DMSO, 50µM LY294002, 200nM Wortmannin, or 10µM 
U0126, stimulated with 10 ng/ml EGF, and Rac activation was assessed by GST-PBD 
pulldown. The total lysates were probed with phospho- EGFR, Akt, ERK 1/2 and total 
Rac as a loading control (A). YAMC cells were transiently transfected with dominant 
negative (DN) Akt1 or Akt2 and Rac activation was assessed as in A. Transfection of
DN Akt was assessed by Western blot analysis for phospho-Akt or HA (B).
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used to confirm the data obtained with U0126.  YAMC cells were pre-treated with 
DMSO, 50µM LY294002, or the MEK 1/2 inhibitors 10µM U0126 and 10µM PD98059.  
The cells were stimulated with 10 ng/ml EGF for 3 minutes, lysed, and Rac activation 
was assayed.  Consistent with the previous experiment, Rac was activated in cells treated 
with the MEK 1/2 inhibitors, but not in cells treated with the PI3K inhibitor (Figure 20).  
Western blot analysis confirmed that both of the MEK 1/2 inhibitors blocked activation 
of ERK 1/2, and that Akt activation was blocked by the PI3K inhibitor (Figure 20).  
These data are also consistent with the time course presented in Figure 11B in which Rac 
is activated prior to Akt and ERK 1/2 activation, suggesting that these proteins do not act 
upstream of Rac.   
 
Src family kinases are required for Rac activation 
Src family kinases are activated in response to EGF treatment (Osherov and 
Levitzki, 1994), resulting in phosphorylation of Src targets and phosphorylation of EGFR 
on several tyrosine residues (reviewed in (Jorissen et al., 2003)).  Because Src family 
kinases play a key role in activation of EGFR and its downstream signaling pathways, the 
involvement of Src family kinases in EGF stimulated Rac activation was investigated. 
Because available pharmacological inhibitors do not inactivate the Src family members 
equally, three different inhibitors, CGP77675, PP1, and PP2 were used in these 
experiments.  All three of these inhibitors were tested in a concentration curve to 
determine the lowest concentration that inhibits phosphorylation of FAK on tyrosine 925 
(a Src specific phosphorylation site) in response to EGF without inhibiting the 
phosphorylation of EGFR, as determined by phosphorylation of tyrosine 1173 (data not  
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Figure 20. MEK 1/2  and ERK 1/2 activity are not required for Rac activation. 
Serum-starved YAMC cells were pre-treated with DMSO, 50µM LY294002, 
10µM U0126, or 10µM PD98059 prior to 10 ng/ml EGF stimulation and Rac 
activation was assessed by GST-PBD pulldown. The total lysates were probed 
with phospho-Akt, phospho-ERK 1/2, or total Rac, ERK 1/2, and Akt as loading
controls.
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shown).  YAMC cells were pre-treated with vehicle only (DMSO) or the Src inhibitors at 
2µM CGP77675, 12.5µM PP1, and 7.5µM PP2 prior to stimulation with 10 ng/ml EGF 
for 3 minutes and Rac activation was assessed.  As shown in Figure 21A, Rac activation 
was reduced in the presence of all three Src inhibitors compared to DMSO treated cells.  
Treatment of YAMC cells with Src inhibitors did not change EGF stimulated EGFR 
phosphorylation at tyrosine 1173, a major phosphorylation site, or activation of ERK 1/2.  
The efficacy of the inhibitors was confirmed by Western blot analysis for 
phosphorylation of FAK at tyrosine 925, which was inhibited by all of these inhibitors, 
but to varying degrees.  Interestingly, the ability of these inhibitors to block FAK 
phosphorylation correlated with their ability to inhibit Rac activation.  Because Src 
family kinase inhibitors effectively blocked Rac activation, these inhibitors were also 
tested in a wound healing assay to determine if Src family kinases are required for EGF 
stimulated wound closure.  YAMC cells were treated with vehicle only (DMSO) or each 
of the Src inhibitors in the absence or presence of EGF and wound closure rates were 
determined.  As shown in Figure 21B, each of the Src inhibitors blocked EGF stimulated 
wound closure.  Interestingly, CGP77675 was the most effective inhibitor of Rac 
activation and FAK phosphorylation at tyrosine 925 and also inhibited EGF stimulated 
migration to the greatest extent (Figure 21 A and B). 
Previous work from our laboratory demonstrated that Src family kinases Src, Fyn, 
and Yes are expressed in YAMC cells, but only Src and Fyn are activated in response to 
EGF treatment (Frey et al., 2004).  To further investigate the role of each of these Src 
family members in Rac activation, small-interfering RNA (siRNA) was used to 
specifically reduce the expression of Src or Fyn in YAMC cells.  Rac1 siRNA was used  
A.
B.
0
10
20
30
40
%
 w
ou
nd
 c
lo
su
re
 a
t 8
 h
ou
rs
Control
EGF*
DMSO CGP PP1 PP2
GTP-Rac
Total Rac
pYFAK
pYEGFR
pERK 1/2
3  ʼEGF:
DMSO  CGP PP1 PP2
Src Inhibitors
-    +     -    +     -    +    -     +
Figure 21. Src family kinases are required for EGF stimulated Rac activation and
migration. Rac activation was assessed in YAMC cells pre-treated with DMSO, 
2µM CGP77675, 12.5µM PP1, or 7.5µM PP2 in the presence or absence of 
10 ng/ml EGF. Western blot analysis was performed for phospho- FAK, EGFR, 
ERK 1/2, and total Rac (A). Cell migration was assessed in YAMC cells in the 
presence of Src inhibitors treated with or without 10 ng/ml EGF.  * p value < 0.001
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as a positive control for inhibition and non-targeting siRNA was used as a negative 
control.  YAMC cells were transiently transfected with non-targeting, Rac1, Src, or Fyn 
murine siRNA smart pools.  Each smart pool contains four different short interfering 
RNA duplexes specifically designed to knockdown mRNA levels of the target gene, 
resulting in decreased protein expression.  Western blot analysis confirmed that Rac, Src, 
and Fyn protein levels were specifically reduced in cell transfected with the 
corresponding siRNA smart pools, although only partially (Figure 22).  Reduction of Rac 
protein levels decreased Rac activation in response to EGF, as expected.  Interestingly, 
decreased levels of Fyn, but not Src, reduced the activation of Rac in response to EGF.  
While the Src inhibitors used in the previous experiment inhibited phosphorylation of 
FAK at tyrosine 925, reduction of Src or Fyn expression only slightly reduced FAK 
phosphorylation, suggesting that the pharmacological inhibitors were more potent than 
the siRNA at inhibiting Src family kinase activity.  Inconsistent with the previous 
experiment using Src pharmacological inhibitors, phosphorylation of EGFR at tyrosine 
1173 was slightly reduced in both the Src and Fyn siRNA transfected cells in this 
experiment, but this result was not consistently observed.  Decreased expression of Rac 
did not inhibit activation of FAK, Akt, or ERK 1/2, demonstrating that Rac is not 
required for signaling upstream of these pathways.  These data suggest that activation of 
Fyn, but not Src, by EGF may be upstream of Rac activation.        
 
Src and PI3K synergize to activate Rac 
While I observed significantly reduced activation of Rac with either PI3K or Src 
inhibitors, Rac-GTP was still stimulated in response to EGF treatment.  Therefore, it was  
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Figure 22. Reduced expression of Rac or Fyn inhibits Rac activation. YAMC cells
were transfected with 50nM Non-targeting, Rac, Src, or Fyn siRNA, serum-starved, 
and then treated with or without 10 ng/ml EGF for 3 minutes.  Rac activation was 
assessed by GST-PBD pull-down.  Rac, Src, and Fyn Western blot analysis 
confirmed that siRNA transfections were effective.  The total lysates were also 
blotted with phospho-EGFR (pY1173), FAK, Akt, and ERK 1/2 to detect activation 
of these proteins. 
50nM siRNA:
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plausible that Src and PI3K act in parallel pathways to activate Rac.  To test this, YAMC 
cells were again pre-treated with vehicle only (DMSO), 50µM LY294002, 2µM 
CGP77675, or concomitantly with 50µM LY294002 and 2µM CGP77675, and EGF 
stimulated Rac activation was assessed.  While treatment of YAMC cells with LY294002 
or CGP77675 incompletely inhibited Rac activation as shown above, the combination of 
both LY294002 and CGP77675 completely blocked Rac activation in response to EGF 
(Figure 23). These inhibitors did not affect EGF stimulated EGFR phosphorylation on 
tyrosine 1173, showing that the inhibitors did not have a non-specific effect on EGFR 
activation. CGP77675 alone or in combination with LY294002 blocked FAK 
phosphorylation at tyrosine 925, while LY294002 alone did not inhibit FAK Y925 
phosphorylation. LY294002 alone or in combination with CGP77675 completely blocked 
activation of Akt, while CGP77675 alone did not.  These data confirm that both Src and 
PI3K contribute to Rac activation in response to EGF, suggesting that these kinases act in 
parallel pathways downstream of EGFR activation and upstream of Rac activation.   
 
Effect of tyrosine mutations on EGF stimulated signaling and migration  
Phosphorylated tyrosine residues in the C-terminal tail of EGFR create binding 
sites for proteins containing SH2 and PTB domains.  Mutational analyses of EGFR 
autophosphorylation sites have revealed a number of binding partners and their preferred 
tyrosine residues as shown in Figure 7.  Tyrosines 1068 and 1086 have been shown to 
bind to Grb2, which couples to Gab1 to activate PI3K in response to EGF.  Having 
demonstrated that PI3K is required for Rac activation, I hypothesized that mutation of 
tyrosines 1068 and 1086 would inhibit EGF stimulated cell migration.  Because the  
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Figure 23. PI3K and Src family kinases synergize to activate Rac. YAMC cells
were pre-treated with DMSO, 50µM LY294002, 2µM CGP77675, or 50µM
LY294002 and 2µM CGP77675, stimulated with 10ng/ml EGF and Rac 
activation was assessed with GST-PBD pulldown. Activation of EGFR (pY1173), 
FAK, and Akt in the total lysate was assessed by Western blot analysis using 
phospho-specific antibodies.  Equal loading was confirmed by Western blot 
analysis for Rac. 
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autophosphorylation sites required for Src activation are not known, I also wanted to test 
the requirement of other tyrosine residues for EGF stimulated cell migration.  EGFR-/- 
MCE stable cell lines expressing single tyrosine to phenylalanine (F) mutations at 
residues 992, 1045, 1068, 1086 were generated in the same manner as the vector, wild 
type, and kinase dead stable cells described above.  Tyrosines 992 and 1173 have both 
been shown to bind to PLCγ1 and Shc, suggesting that these tyrosines have redundant 
functions.  Similarly, tyrosines 1068 and 1086 have both been identified as binding sites 
for Grb2, so double mutants of F992/F1173 and F1068/F1086 were also generated.  After 
generating cells stably expressing these various mutants in collaboration with Toshimitsu 
Yamaoka, I determined their ability to respond to EGF treatment by treating serum 
starved cells with 10 ng/ml EGF for 3 minutes.  The cells were lysed and immunoblot 
analysis for EGFR, phospho-Akt, and total phosphotyrosine was performed (Figure 24).  
Compared to wild type and kinase dead stable cells, the EGFR mutants were expressed to 
similar levels, except the double mutation of F992/F1173, which is expressed at very low 
levels (Figure 24).  Interestingly, Akt was activated in response to EGF in all of the 
mutants, including the double F1068/F1086 mutant.  Akt was not activated in kinase dead 
EGFR stable cells, confirming that EGFR kinase activity is required for its activation.  
These data suggest that none of the tyrosine mutations tested inhibit EGF stimulated 
PI3K activation.  Total phosphotyrosine immunoblot analysis revealed that the double 
mutants F992/F1173 and F1068/F1086 show reduced phosphorylation of a high 
molecular weight band that most likely represents EGFR.  The profile of EGF stimulated 
phosphotyrosine looked similar between wild type, F1045, F1068, and F1086 suggesting 
that these mutations do not have much effect on downstream signaling (Figure 24).  
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Figure 24. EGF treatment of EGFR-/- MCE stable cells expressing EGFR tyrosine 
to phenylalanine mutations. EGFR-/- MCE stable pools of wild type, kinase dead, 
or tyrosine to phenylalanine mutants F1045, F11068, F1086, F992/F1173, and 
F1068/F1086 cells were serum starved and then treated with or without 10ng/ml 
EGF for 3 minutes.  Cell were lysed and Western blot analysis for total EGFR, 
phospho-AKT or phosphotyrosine was performed.
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 Based on the results from the signaling data, I hypothesized that the individual 
tyrosine mutations would not inhibit EGF stimulated migration.  To determine the effect 
of these mutations on migration, YAMC, EGFR-/- MCE cells expressing vector, wild 
type, kinase dead, or tyrosine to phenylalanine mutations were subjected to wound 
healing assays.  To allow comparison of the data from different wound healing assays, 
the fold increase in EGF stimulated wound closure over control was calculated.  Using 
this calculation, the control wound closure is set at 1 and the change in wound closure 
with EGF is determined relative to control.  Data from several different wound closure 
assays were then combined and the average fold increase in wound closure was 
calculated and graphed (Figure 25).  Surprisingly, individual tyrosine mutations F1068, 
F1086, and F1045 significantly reduced EGF stimulated migration compared to wild type 
cells.  Mutation of tyrosine 992 had no effect on EGF stimulated migration compared to 
control, suggesting that the inhibition is specific for individual tyrosines.  F992/F1173 
double mutation inhibited EGF stimulated migration, suggesting that tyrosine 1173 is 
also required for migration, but generation of the single F1173 mutant is needed to 
confirm this.  These data suggest that although mutation of individual tyrosine residues 
does not inhibit EGF responsiveness (Figure 24), some of these tyrosine residues 
specifically contribute to cell migration (Figure 25), demonstrating the complexity of 
signaling that contributes to a migratory response.   
 
Discussion 
These experiments have dissected the pleiotropic effects of EGFR activation to 
identify specific pathways involved in EGF stimulated Rac activation and cell migration.                                                                                                                                            
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Figure 25. Migration of EGFR-/- MCE stable cells expressing EGFR tyrosine to 
phenylalanine mutations. YAMC cells or EGFR-/- stable pools expressing empty 
vector, wild type, kinase dead, or tyrosine to phenylalanine mutations F992, 
F992/F1173, F1068, F1086, and F1045 were serum starved, wounded in the absence 
or presence of 10 ng/ml EGF and the percent wound closure was calculated.  The 
fold increase in migration was calculated by dividing the average percent wound 
closure in the presence of EGF by the average percent wound closure in the control 
cells.  The control cell migration was set to a value of 1.  Several different 
experiments were combined and the standard deviation was calculated to account 
for variability between experiments.  The combined data from several different 
experiments is respresented. 
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The data presented in these studies demonstrate that both PI3K and Src family kinase 
activities are required for EGF stimulated Rac activation.  However, PLCγ, PKC, Akt, 
and MEK 1/2 activities are not required for Rac activation, demonstrating the specificity 
of signaling through PI3K and Src activity to Rac.  While several of the signaling 
pathways examined do not contribute to Rac activation, the complexity of signaling 
involved in EGFR-mediated cell migration is demonstrated by the inability of tyrosine to 
phenylalanine EGFR mutants to migrate in response to EGF.  These data suggest that a 
complicated signaling network is required for EGF stimulated migration, of which Rac 
activation is one component.  Because cell migration is a multi-step process that requires 
coordination of many different events to successfully more forward, inhibition of any of 
these steps is likely to result in decreased migration.   
Previous data from our lab and others has shown that PLC activity and subsequent 
activation of PKCs are required for EGF stimulated migration (Chen et al., 1994b) (Polk, 
1998).  Consistent with these reports, mutation of the tyrosines on EGFR required for 
PLC binding, tyrosines 992 and 1173, results in decreased cell migration in response to 
EGF (Figure 25).  However, my experiments using pharmacological inhibitors 
demonstrated that PLC and PKC are not involved in Rac activation in YAMC cells, 
suggesting that increased lamellipodia formation and Rac membrane translocation in 
response to EGF treatment occur independently of signaling pathways activated by PLC.  
Interestingly, a decrease in PtdIns 4,5-P2 and an increase in IP3 generation was observed 
at the leading edge of EGF stimulated fibroblasts and was proposed to be the result of 
increased PLC activity at the leading edge (Chou et al., 2002).  Subsequent studies by the 
same group suggested that PLC activates Cdc42 to promote directed cell migration in 
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response to EGF (Chou et al., 2003).  These data, in combination with my data, suggest a 
model in which PLC hydrolysis of PtdIns-4, 5-P2 activates Cdc42 at the leading edge, 
while PI3K phosphorylation of PtdIns-4, 5-P2 activates Rac at the leading edge, both 
promoting increased migration.  Although both of these pathways are required for EGF 
stimulated migration, they appear to function in parallel because PI3K, but not PLC, is 
upstream of Rac activation.  One possibility is that competition of these enzymes for a 
similar substrate, PtdIns-4, 5-P2, at the membrane may determine the timing of which 
pathways are stimulated.  
Since the initial studies in which EGF was described as a potent mitogen for 
cultured cells, much work has focused on characterizing the mechanism of EGFR-
mediated proliferation.  Recruitment and binding of the adaptor proteins Grb2 and Shc to 
the C-terminus of phosphorylated EGFR activates the small GTPase Ras, which in turn 
activates the canonical Ras-Raf-MEK-ERK kinase cascade, resulting in increased 
proliferation.  Studies performed in fibroblasts and liver epithelial cells have 
demonstrated that increased cell motility induced by EGF occurs independently of 
increased proliferation (Chen et al., 1994a) (Geimer and Bade, 1991).  Work from our lab 
has demonstrated that proliferation is reduced in EGF treated cells near the wound 
margin, suggesting that proliferation and migration are independent biological responses 
downstream of EGFR (Corredor et al., 2003).  In agreement with these reports, 
pharmacological inhibition of the MAPK cascade using two different MEK 1/2 
inhibitors, U0126 and PD98059, did not alter Rac activation in response to EGF (Figures 
19A and 20), suggesting that the signaling pathways upstream of Rac activation are 
independent from proliferative signaling pathways.  This is also consistent with the 
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kinetics of ERK 1/2 phosphorylation observed in Figure 11B, in which GTP-Rac 
stimulation occurs prior to ERK 1/2 activation.  These data further support the idea that 
our cell culture model of wound healing mimics the in vivo response to injury in which 
restitution occurs rapidly, prior to and independent from the proliferative response 
observed during regeneration.    
In these studies, I have demonstrated that PI3K is required for Rac activation, in a 
mechanism independent of Akt activation.  When activated, PI3K generates a localized 
concentration of 3’ phosphorylated phospholipids at the plasma membrane.  The 
requirement for PI3K activity suggests that a PH-domain containing protein is required 
for Rac activation.  While activity of the Rho GTPases is regulated by GDIs and GAPs, 
data suggest that the most important factor influencing activation is the regulation of 
GEFs (Schmidt and Hall, 2002).  Currently 69 mammalian GEFs have been identified, 
most of which contain a characteristic pleckstrin homology (PH) domain and a Dbl 
homology (DH) domain, making them obvious candidates for the missing link 
downstream of PI3K (Rossman et al., 2005).  However, the identity of the putative GEF 
involved in EGF stimulated Rac activation is currently unknown.  Although a small 
number of GEFs have been well characterized, the remaining GEFs are either novel or 
their GTPase specificity has not been determined, making it difficult to predict which of 
the 85 family members are candidate GEFs for Rac.  While tissue distribution of these 
proteins limits the number of GEFs present in any given cell type, we do not know which 
GEFs are expressed in YAMC cells.  Microarray data from our lab confirms that mRNA 
for at least 15 different is GEFs is present in YAMC cells (data not shown).  Additional 
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GEFs are likely expressed in YAMC cells because many of the known GEFs were not 
represented on the microarray chip used in this experiment.    
The rapid and transient activation of Rho GTPases suggests that GEFs are tightly 
regulated; however, a common mechanism of regulation has not been established.  Some 
of the GEFs, such as Vav-2, a GEF for Rho, Rac, and Cdc42 are activated by 
phosphorylation events, placing them at the top of the list for candidate GEFs involved in 
EGF stimulated Rac activation.  In particular, Vav-2 has been shown to co-
immunoprecipitate with activated EGFR and is tyrosine phosphorylated in response to 
EGF treatment of HeLa cells (Pandey et al., 2000).  Although Vav2 is expressed in 
YAMC cells, I was unable to detect either tyrosine phosphorylation of Vav2 or 
association of Vav2 with EGFR in response to EGF in YAMC cells (data not shown).  
GEF activation also requires its translocation to the plasma membrane through the GEF 
PH domain, which binds to 3’ phosphorylated PtdIns generated at the plasma membrane 
when PI3K is activated. Based on my inhibitor studies, I propose that EGF stimulated 
PI3K activity recruits the GEF to the plasma membrane, bringing it into proximity with 
activated EGFR and Src, where it can be further activated through phosphorylation.  The 
hematopoietic-specific GEF Vav1 is one example of a GEF that is regulated by Src 
family kinases.  Phosphorylation of Vav1 at tyrosine 174 in the N-terminus by Src family 
kinases relieves an intramolecular inhibition and exposes the DH domain of the protein to 
facilitate its exchange activity (Aghazadeh et al., 2000).  The synergistic effect of 
inhibiting both Src and PI3K suggests that these pathways independently contribute to 
activation of Rac (Figure 23).  This supports a model in which generation of 
phospholipids at the plasma membrane can recruit and active the GEF to a small extent, 
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and likewise, Src phosphorylation can weakly activate the GEF.  When both kinases are 
fully activated in response to EGF treatment, maximal GEF activation is achieved.  
Inhibition of PI3K does not inhibit activation of FAK phosphorylation (Figure 23), which 
is inhibited by all of the Src inhibitors used (Figure 21A), demonstrating that PI3K is not 
upstream of Src in this system.  Similarly, inhibition of Src family kinases does not block 
Akt phosphorylation, demonstrating that PI3K activation is independent of Src (Figure 
23).  
An alternative model for these data is that phosphorylation of a Src-specific 
tyrosine residue within EGFR recruits and activates adaptor proteins required for Rac 
activation.  EGF stimulated activation of Src results in phosphorylation of EGFR on 
tyrosines 845 and 1101 by Src (Biscardi et al., 1999a).  It is possible that activation of 
Rac requires signaling through these tyrosine residues; however, generation of stable 
cells expressing a mutant F845/F1101 EGFR is necessary to test this.  While mutational 
analysis of EGFR has revealed a number of tyrosines involved in EGF stimulated 
migration, these mutants have not yet been tested for their ability to activate Rac.  
Assessment of the ability of various mutants to activate Rac will further define the 
individual signaling pathways that contribute to EGF stimulated cell migration.  For 
example, tyrosines 1068 and 1086 both bind to Grb2, suggesting that their binding 
partners are redundant (Figure 7).  Surprisingly, mutation of these tyrosines individually 
inhibits EGF stimulated cell migration, suggesting a more complicated signaling network 
exists downstream of these tyrosine residues.  As demonstrated in Figure 24, the 
signaling pathways disrupted by these tyrosine mutations have not been identified.  
Characterization of the specific signaling pathways downstream of these tyrosines will 
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further our understanding of the biological function of EGFR, as well as the role of these 
signaling pathways in growth factor stimulated motility. 
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CHAPTER V 
 
FUTURE DIRECTIONS AND CONCLUSIONS 
 
Future directions 
Cell migration requires coordinated activation of several different Rho GTPases, 
namely, Rac, Rho, and Cdc42 (reviewed in (Raftopoulou and Hall, 2004)). In the 
experiments presented here, I demonstrate that the small GTPase Rac1 is required for 
EGF stimulated migration of intestinal epithelial cells.  However, these studies do not 
address the role of Cdc42 and Rho in cell migration induced by EGF.  While in some of 
my experiments weak Cdc42 activation was detected in response to EGF treatment 
(Figure 11A), I was not able to consistently detect this activation.  The observation that 
filopodial extensions direct the formation of lamellipodia suggests that Cdc42 activation 
is upstream of Rac (Nobes and Hall, 1995).  To address this question, I will utilize siRNA 
smart pools targeting Cdc42 to reduce the expression of Cdc42, followed by wound 
healing assays and Rac activation assays in the presence or absence of EGF.  These 
experiments will determine whether EGFR can activate Rac in the absence of Cdc42 or if 
Cdc42 is required for EGFR to elicit these responses.  Previous work in intestinal 
epithelial cells has demonstrated that the small GTPase Rho is required for EGF induced 
migration in a scratch wound assay (Santos et al., 1997).  To determine if Rho is 
activated in YAMC cells, I will use a GST fusion protein of the Rhotekin Rho-binding 
domain to pull down active GTP-Rho from total cellular lysates after treatment with EGF 
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for various times (Ren et al., 1999).  These studies will elucidate the contributions of 
other GTPases to EGF stimulated intestinal epithelial cell migration.  
While we do not yet understand how the other GTPases contribute to EGF 
stimulated migration, I have demonstrated that Rac is rapidly and robustly activated in 
YAMC cells in response to EGF treatment.  This activation likely occurs through the 
activation of a GEF downstream of EGFR; however, the identity of the GEF involved in 
EGF stimulated Rac activation in YAMC cells is unknown.  A new method to identify 
activated GAPs and GEFs from total cell lysates has just been described (Garcia-Mata et 
al., 2006).  In this assay, a GST-fusion protein encoding a mutated Rho GTPase 
specifically binds to activated GAPs or GEFs.  The activated GEF or GAP is then 
identified either by Western blot analysis for candidate proteins, or by mass spectrometry.  
I will use this assay to identify Rac-specific GEFs that are activated in response to EGF 
treatment.  If the GEF can be identified, further studies will be performed to characterize 
the Rho GTPase specificity of this GEF.  Because my studies suggest that Src and EGFR 
kinase activity are required for Rac activation, I would also like to determine if the GEF 
is regulated by tyrosine phosphorylation.  The role of this GEF in EGF stimulated cell 
migration will be determined using siRNA directed against the GEF to reduce the 
expression of this protein and wound healing assays will be performed.  I can also use 
siRNA experiments to determine the role of this GEF in Rac activation in response to 
wounding, EGF treatment, or the combination of the two.  These studies will determine if 
the same GEF is involved in basal and EGF stimulated migration, providing further 
insight into the mechanism by which EGF activates Rac.  
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As described in these studies, we have recently generated a panel of stable cell 
lines expressing tyrosine to phenylalanine EGFR mutants in cells devoid of endogenous 
EGFR.  Much work needs to be done to further characterize the signaling pathways, if 
any, that are disrupted by these mutations.  In particular, the inability of several different 
mutants to migrate in response to EGF suggests that signaling pathways downstream of 
these individual sites are required for cell migration.  Determining the signaling pathways 
altered by these mutations will contribute to our understanding of signaling through 
EGFR as well as our knowledge of the how cell migration is regulated by EGFR.  As 
many different pathways contribute to EGF stimulated migration, I will assess the ability 
of each of these mutants to activate Rac in response to EGF to parse out the tyrosines 
required for Rac versus other migratory signals.  These mutants will also be assessed for 
their ability to proliferate in response to EGF treatment in an attempt to identify 
downstream signaling pathways required for migration, proliferation, or both processes. 
These experiments will expand my current studies to further characterize the mechanisms 
that regulate cell migration downstream of EGFR activation. 
 
Conclusions 
The process of cell migration is critical throughout the human life cycle, and in 
particular, tight regulation of cell migration is required to maintain a healthy 
gastrointestinal tract.  In this study, I have extended our previous observations of EGF 
stimulated wound closure and identified a mechanism by which EGFR accelerates cell 
migration.  I demonstrate that the small GTPase Rac is required for EGF stimulated cell 
migration in a wound healing assay that mimics the process of restitution in response to 
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injury.  YAMC cells exposed to EGF rapidly activate Rac and exhibit increased 
lamellipodial extensions at the wound margin, resulting in increased cell motility.  Two 
downstream targets of EGFR, Src family kinases and PI3K, are required to activate Rac 
in response to EGF treatment. These data suggest a novel signaling cascade downstream 
of EGFR activation leading to a rapid increase in cell motility that is independent of the 
proliferative (ERK 1/2) and cell survival (Akt) pathways stimulated upon EGFR 
activation.  These data are consistent with the current model of intestinal repair in which 
restitution occurs immediately after wounding to restore the epithelial integrity, followed 
by a phase of regeneration to repopulate the damaged area (Okamoto and Watanabe, 
2005).  Together, these data demonstrate a novel pathway whereby EGFR activation 
increases wound closure through the synergism of two different kinase cascades that 
induce actin-based motility via the small GTPase Rac. These data contribute to our 
knowledge of the complex molecular mechanisms that control intestinal epithelial repair 
with implications for understanding the role of growth factor regulation of this small 
GTPase in intestinal cellular migration and differentiation programs in vivo.  Elucidation 
of the mechanisms that regulate intestinal epithelial cell migration will allow the 
development of more specific therapeutic treatments for inflammatory bowel diseases.  
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